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Recent growth in nanotechnology has been accelerating the identification 
and evaluation of new drug candidates. The development, optimization of 
nanomedicine and preclinical assessment of drug-induced toxicity as well as 
efficacy, is critical, but long and expensive. These studies are challenging due to 
the lack of test platforms that can incorporate sufficient human-relevant 
physiological complexity for reliable and standardized prediction of drug effects. 
Current preclinical drug testing, which rely predominantly on animal models, is 
expensive and has poor predictivity due to the variety of animals and limitation of 
imaging technologies. Two-dimensional (2D) cell cultures have also been used in 
the preclinical phase drug screening, however, they cannot adequately restore 
original cellular behaviors to nanomedicine in three-dimensional (3D) tissues. 3D 
cell culture techniques have enabled the real-time study of mammalian tissues 
within ex vivo models. These models with the ability to independently manipulate 
microenvironmental factors can be used to explore fundamental biological response 
to novel therapeutic nanoparticles and enable testing of novel therapeutic 
approaches.  
Drug delivery and transport of nanomedicine through complex 3D tissues 
such as solid tumors can be adequately evaluated in specially prepared 3D cell 
culture as platform. This is an important consideration for pharmacodynamics 
xxii 
 
analysis to validate drug doses and administration regimens required to achieve 
desired therapeutic effects.  In coupling with computational Monte-Carlo 
sampling and analysis of conditioned microenvironment, the standardized and 
uniform-sized liver tumor spheroids culture model in Inverted Colloidal Crystal 
(ICC) scaffolds in vitro could be used to identify or validate predictive drug 
transport and efficacy, while the transparency of the platform allowed convenient 
real-time monitoring of drug-cellular interaction. As a potential solution to improve 
the predictive power of ex vivo screening procedures, this dissertation established 
the experimental and conceptual framework for quantitative evaluation of drug 
delivery and transport in the tumor tissue ex vivo as a part of drug discovery, and 
explored a new opportunity of carbon nanotubes as a promising nano-sized carrier 
for drug delivery.  
Besides the primary goal of drug delivery and transport in 3D complex, 
these models have been studied to generate replacement human tissues using 
patient-derived cells and/or stem cell. This is essential for future personalized drug 
screening and personalized medicine, as well as co-clinical trial applications with 
a patient’s own cells adapted with stem cell techniques. It is able to develop patient-
specific model for individualized study of drug safety and efficacy or drug–drug 
interactions. In this part of dissertation, ICC scaffolds with uniformly, controllable 
porous structure combined with a layer-by-layer (LBL) bone mimetic modification 
technique served as a platform for engineered stem cells towards optimal hepatic 
differentiation and hepatocyte formation for discovery of personalized drug testing. 
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Bone marrow stromal cells as supporting layer for stem cell culture was found 
interacting and influenced by surface properties of 3D matrices. 
Overall this dissertation introduces a promising and standardized 3D cell 
culture platform established in ICC scaffolds coupling with computational 
simulation which substantiate the capability in a range of areas in preclinical drug 
discovery. This platform is a window to fundamental understanding of 
nanomedicine, as well as a practical and valuable tool for drug discovery regarding 
drug delivery and transport through complex 3D tissues, as well as development of 










Nanotechnologies have been recognized as successful therapeutic 
interventions including various aspects from engineered drug delivery and 
localization to personalized medicine1–4,5,6. The advances such as unique optical 
properties and surface chemistry in nanomedicine are accelerating the identification 
and evaluation of these drug candidates7,8,9–11. Yet, as nanomedicine is developing, 
the concerns of drug side effect and failures associated with the new technology 
that are involved in the therapeutic procedure have been brought to public attentions. 
To transform these new therapeutic technologies into medical reality, explosive 
efforts have been accumulated on preclinical assessment and prediction regarding 
effectiveness and toxicities.12 Whereas, the pharmaceutical industry is facing 
unprecedented challenges due to high costs and the inefficiency of novel drug 
research and development. 13  In addition, attrition aroused out of safety liabilities 
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observed in the clinical application are the major contributor to the rising costs and 
reduced productivity in the industry 14 because potential issues cannot be identified 
during preclinical development. These are the consequences of the long process15 
(Figure 1.1a) and poor prediction of existing preclinical models16 (Figure 1.1b) 
which have led to demands for more accurate predictive tools.  
Two-dimensional (2D) cell cultures as a conventional and convenient tool 
were therefore often accepted for toxicity and targeting studies17,18. However, they 
are not able to adequately represent tissue morphology to replicate realistic 
conditions. Test Animal models, such as rats, mice and hamsters, have been widely 
used regarding different nanoparticles (NPs). The existing data were obtained for  
 
Figure 1.1 The predictivity of preclinical models including human tissue-based 
approaches instead of animal models shows the necessarity of new preclinical 
approaches for pharmacology studies.15,16,19  
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various tumors, therapeutic, modalities, administration routes, doses, however, 
quantification methods and numerous unexpected properties of NPs cannot be 
reliably measured and standardized by such animal models18,19. For instance, the 
numbers of mice in published studies are too small, making it difficult to obtain 
statistically significant comparisons; the experimental conditions, such as relative 
tumor size at the start of treatment, are not comparable to those in the human  
population; moreover, the drug doses used and tolerated in mice are also too 
divergent for use in people. Therefore, the results from classic tests of toxicity and 
efficiency is questionable and may potentially lead to unjustified conclusions of the 
conducted tests to humans. Moreover, numerous the experimental therapies of 
nanomedicine were found lack of therapeutic efficacy. This is due to the poor 
prediction from mouse models of cancer that does not apply to human trials. 
(Figure 1.1b)  To sum up, the preclinical models which can be systematically 
identified to generate standardized and reliable predictions for novel drug efficacy 
and safety in humans in preclinical process has been critically needed for 
application of  nanomedicine.20  
What features should an ideal preclinical model have? A list of potential 
advantages or disadvantages should be considered: Is the model convenient to work 
with? Does it model the complexities of the genetic background of the patient 
population and the mutational load and heterogeneity observed in human tumors? 
Does it model the tumor environment and functions? How stable the model is in 
long-term study? Can we extract quantitative data from the model and can these 
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data be generalized? Recent advances in microfabrication, microfluidics and stem 
cell technologies have enabled the development of preclinical models ex-vivo that 
could provide the basis for preclinical assays and standard with greater predictive 
power. These ex-vivo models such as three-dimensional (3D) cell cultures 21,22, 
ranged from functional units of human organs (Organ-on-a-chip)14,23 to explant 
tissue culture24–26. New opportunities have emerged for the application of these 
models in preclinical drug discovery27, such as target identification and validation, 
target-based screening, and phenotypic screening in a standardized, statistical, 
reproducible and personalized manner.  
1.2 Current ex-vivo 3D culture models for drug discovery 
For the discovery and evaluation of new drugs, nowadays ex-vivo models 
such as 3D cell cultures provide various advantages over conventional 2D cell 
cultures. These models can represent complex physiology in vivo to evaluate drug 
responses, and at the same time they are able to provide large amounts of relatively 
inexpensive but significant data as 2D models for prediction of therapeutic 
properties incorporated with computational modelling and systematical approaches.  
3D cell culture systems have first drawn much attention and gained 
increased recognition as important drug evaluation tools a decade ago 28. For 
instance, early-developed 3D culture systems have been applied to study 
phenomena29–31, such as drug resistance and cell invasion 32. Ex vivo cultures of 
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primary tissues are also to be included as 3D culture systems, however, the variety 
of tissue samples are difficult to standardized or to achieve the statistical 
significance for drug screening.32,33 3D cell cultures embedded in matrix and 
scaffolds are increasingly utilized because the potential of high throughput testing 
enable the large quantitative data to investigate differentiation and invasion 
processes of tumor cells triggered by factors from extracellular matrix.34,35 Much 
progress of drug testing in 3D models has been made in natural and artificial 
matrices based on scaffolds (Table 1.1) 36,14. These promising methods improve 











Table 1.1 Three-dimensional cell culture matrices based on scaffolds 14 
 
 
These ex-vivo tissue-like matrices have been largely used to establish 3D 
spheroid-based models to recapitulate the structural and functional complexity of 
human organs37 (Figure 1.2) such as the liver, heart, lung, intestine, kidney, brain 




Figure 1.2 Designing spheroid-based ex-vivo platforms mimicking different in-
vivo microenvironments. Here shows the architectural complexity at each of the 
diverse microenvironments in which both cell type and extracellular environment 
might affect treatment efficacy. 36, 37 
These can also reconstitute complex organ-level physiological functions, 
clinically relevant disease phenotypes and pharmacological responses that arise 
from structural and functional integration of multiple tissue or organ types. This 
characteristic allows more comprehensive and accurate preclinical predictions ex 
vivo for complex problems. To better mimic the physiological conditions in vivo, 
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fluid motions and cell culture substrates can also be controlled to reproduce various 
types of cues in the spheroid-based models38,39 However, while designing 3D 
culture models with optional conditions, the increasing complexity have caused 
expensive and sometimes unnecessary procedures. Therefore, the specific 3D ex-
vivo cell culture model based on needs are the future direction in preclinical models.  
 
1.3 Challenges for NP transport in tumor for drug delivery  
NPs, such as gold nanoparticles (AuNPs) and carbon nanotubes (CNTs), 
have been widely studied as promising vehicles for drug delivery and localization 
due to their unique properties enabling localization and targeted therapy of many 
diseases40–42.  Large amount of work has focused on the targeting of NPs to specific 
cells and their blood circulation43,44. However, little is known about their transport 
within the tissues after being released from blood vessels, while limited delivery of 
drugs in dense tissues has been identified as one of the primary reasons for 
inefficient cancer therapy (Figure 1.3) 45,46.  Understanding the fundamental of NP 
transport in tissue will facilitate the development and discovery of nanomedicine 
for solid tumors as well as other diseases.  It will also provide the medical and 





Figure 1.3 Distribution of NPs in tumors in vivo. Blood vessels are shown in 
black.46 
 
 Unfortunately, investigation of NP diffusion inside tissues is inherently 
difficult at the moment largely due to the lack of suitable models.  2D culture 
models as standard tools for therapeutic effect or toxicity studies47,48 could not 
replicate the complex morphology and in vivo conditions. Meanwhile, in-vivo 
imaging of animal study was limited by the insufficient resolution and was not able 
to identify NP distribution in real-time in organs and deep tissues49–51, which are 
also variable, and costly. Therefore, ex-vivo studies based on 3D cell culture models 
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become an applicable candidate for NP transport study to minimize the necessity 
of animal studies. 
In the second and third chapters, we aim to better understand of NP 
diffusion in solid tumors, which will aid in development and application of these 
drug carriers and imaging agents for efficient penetration into cancerous tissues. To 
adequately evaluate transport and distribution of NPs inside the tumor tissue in 3D 
cell culture, the models shall meet the following needs: (1) 3D cell culture with 
spheroids-based features experimentally demonstrated similar morphology and 
functions as some original tissues.  (2) The size of the spheroids can be accurately 
controlled with high uniformity which eliminates sample-to-sample variability and 
enables standardized mathematical description of experimental data. (3) Culture 
substrates (scaffolds) shall be high transparent with low scattering in order to 
evaluate NP transport in real time with high resolution imaging equipment.  (4) 
They can also be easily integrated with high-throughput technologies. In the 
dissertation, cell spheroids grown in inverted colloidal crystal (ICC) scaffold 26,52, 
which have the advantages over the other models and simple enough to avoid the 
tradeoff of convenience will be utilized to conduct this study.  
 
1.4 Computer-aided drug development and discovery 
Computer-aided drug discovery methods have played a major role in the 
drug development. It can help researchers to design experiments at the early stage 
of drug development or to better understand experimental data. Many novel 
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computational methods were developed in discovering promising drug 
candidates.53 Much progress has been made in areas such as scoring functions, 
similarity search methods and statistical approaches54,55. These computational tools 
such as Molecular Dynamics (MD) simulation and 
Pharmacokinetic/Pharmacodynamic (PK/PD) modeling are generally used for 
prediction and scoring of activity of new drugs binding in either target of interest56 
or early stage of the structure design57,  as well as prediction and optimization of 
drug metabolism and pharmacokinetics by high-throughput screening58. 
MD simulations, combining Newtonian physics and all-atom, flexible 
representation of proteins, water and other molecules to understand the dynamic 
interactions between them, can provide important qualitative information, such as 
the binding affinities of drugs to cell membrane (Figure 1.4a) 59,60. Recent 
improvements in hardware and algorithms have accelerated the development of this 
method.61 However, drug design is more than just molecular binding, biologic 
activity and selectivity for the target of interest. Meanwhile, once applied to whole 
animal or human, therapeutic drug metabolism and pharmacokinetics properties 
need to be considered as well. PK/PD modeling has been developed to simulate and 
obtain the quantitative information such as drug distribution and metabolism in 
humans. 58,62 Recent PK/PD simulations account for variations in perfusion, 
vascularization, interstitial transport, and non-linear local binding. Based on a 
comparison of the fundamental rates determining uptake, drugs can be classified 
depending on whether uptake is limited by blood flow, extravasation, interstitial 
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diffusion, or local binding and metabolism(Figure 1.4b)63. These parameters 
provides the systemic prediction of drug doses and efficiency within human. 
 
Figure 1.4 (a) the force–displacement profile of CNT during the cell membrane 
penetration by MD simulation. Displacement (A°) refers to the distance between 
the instantaneous and the initial positions of the CNT. (b) PK/PD Simulation results 




These computational tools have been incorporated into the drug discovery 
pipeline before a drug discovery is initiated. However, the corresponding 
experimental and preclinical/clinical validation are still needed to establish the tools 
with statistical significance and reproducibility in human. In another aspect, as ex-
vivo experimental culture models develop, computer-aided data analysis and 
simulation can assist the design of experiment and generalization of the parameters 
for broader application. Therefore, a methodology of realistic model-based 
simulation combined with an ex vivo experimental framework shall be created. This 
integrated platform ex vivo allows better understanding of biophysical behavior 
before and during drug design, drug screening in a high-throughput miniaturized 
format and associated pharmacokinetic simulations to predict in vivo drug 
concentration profiles in a cost effective way for preclinical development of drug 
delivery systems. 
 
1.5 3D cell culture for preclinical personalized drug screening 
Stem cells are able to provide potentially unlimited resources of tissue 
culture for a wide range of toxicity models that could complement the variety of 
animal models from human which is more relevant and personalized. Embryonic 
stem cells (ESCs) have already been proven valuable for drug toxicity tests and 
other mechanistic studies 64,65. Induced pluripotent stem cell (iPSC), which are 
generated by reprogramming human-derived cells back to the status of ESC-like 
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cells, allow the drug discovery and assessment to be designed under the conditions 
of personalized genetic background or medical case history. Pathway perturbations 
that underlie toxicity and disease, enabling the development of predictive assays 
for toxicity can be elucidated by comprehensive profiling of ESC/iPSCs via 
genomics, proteomics, transcriptomics, and metabolomics. This human tissue assay 
is essential to minimize the animal study which is discrepant from human. 
Therefore, incorporation of human stem cell based assays into drug discovery and 
toxicity testing offers the potential for safer and more personalized medicines, as 
well as reduced costs and decreased use of animal models66.  
Significant progress in technology focused on ex-vivo 3D cell/tissue 
cultures has been made, the next step is to consider the integration of stem cell 
technology to create interconnected patient-specific engineered tissues/organs67. 
The use of ESCs or iPSC in 3D cultures can further assemble them into specific 
tissues/organs to replicate in vivo morphology and environment68. Such patient-
specific models require a sophisticated set of tools for 3D cell cultures with 
engineered environment to create controllable and precise interconnected 
tissue/organ structures. Among the advanced methods in the past decades regarding 
the complex 3D cultures and state-of-the-art scaffolding, a particularly exciting 
new development is the ability to explant the living tissue of a patient into 3D 
culture to obtain individualized predictive or prognostic information. So that, it is 
also possible to culture stem-based human tissues using excess material from 
surgery in 3D cell cultures69,70. The most recent development is that iPSC research 
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can be applied to these types of tissue and scaffold systems (Figure 1.5a) for a 
patient-specific drug development model68,71. For instance, a recent study 
developed cerebral organoids from iPSCs in 3D culture and replicated the 
anatomical organization of multiple human brain regions, including cerebral cortex 
71,72 (Figure 1.5b). Moreover, the spheroids derived from iPS cells from a 
microcephaly patient showed complex system disorders in patient case history 
which can be modelled using ex-vivo 3D culture. 
In spite of all the advantages and promise, tremendous work are needed to 
be done for design, optimization and application of these tools. In chapter four and 
five, we discuss the spheroids derived from ESCs grown in 3D scaffolding and 
pursue the optimized conditions for liver organoid model regarding to the scaffold 
design and bone-mimic substrate modification, which is essential for personalized 





Figure 1.5 (a) Stem cell spheroid-based 3D cultures. Stem cells can be used to 
generate organoids that model the architecture and cellular composition of a larger 
organ. Both hESCs and hiPSCs have been used to generate organoids of the kidney, 
lung, intestine, liver, optic cup and brain in the presence of 3D scaffolds and 







1.6 Dissertation Framework 
A major goal of biomedical science in drug development and discovery is 
to translate our understanding of the fundamental principles that govern biological 
systems to improve therapeutic effects on patients. 3D cell culture ex vivo can 
function as an integration point for modelling human tissue or disease in 
experimental systems for fundamental studies and thereby yielding precise answers 
to the questions against new drugs. Achieving the full potential of these methods 
will involve the expertise of biological knowledge, material science and 
computational simulation.   
Drug delivery and transport of nanomedicine through complex 3D tissues 
such as solid tumors can be adequately evaluated in specially prepared 3D cell 
culture as platform. This is an important consideration for pharmacodynamics 
analysis to validate drug doses and administration regimens required to achieve 
desired therapeutic effects.  In coupling with computational Monte-Carlo sampling 
and analysis of conditioned microenvironment, the standardized and uniform-sized 
liver tumor spheroids culture model in ICC scaffolds in vitro could be used to 
identify or validate predictive drug transport and efficacy, while the transparency 
of the platform allowed convenient real-time monitoring of drug-cellular 
interaction. As a potential solution to improve the predictive power of ex vivo 
screening procedures, in chapter 2 and 3 of this dissertation established the 
experimental and conceptual framework for quantitative evaluation of drug 
delivery and transport in the tumor tissue ex vivo as a part of drug discovery, and 
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explored a new opportunity of carbon nanotubes as a promising nano-sized carrier 
for drug delivery.  
In chapter 4 and 5, these models have been studied to generate replacement 
human tissues using patient-derived cells and/or stem cell. This is essential for 
future personalized drug screening and personalized medicine, as well as co-clinical 
trial applications with a patient’s own cells adapted with stem cell techniques. It is 
able to develop patient-specific model for individualized study of drug safety and 
efficacy or drug–drug interactions. In this part of dissertation, ICC scaffolds with 
uniformly, controllable porous structure combined with a layer-by-layer (LBL) 
surface modification technique served as a platform for engineered embryonic stem 
cells towards optimal hepatic differentiation and hepatocyte formation for 
discovery of personalized drug testing. Bone marrow stromal cells as supporting 
layer for stem cell culture was found interacting and influenced by surface 
properties of 3D matrices. 
Overall this dissertation introduces a promising and standardized 3D cell 
culture platform established in ICC scaffolds coupling with computational 
simulation which substantiate the capability in a range of areas in preclinical drug 
discovery. This platform is a window to fundamental understanding of 
nanomedicine, as well as a practical and valuable tool for drug discovery regarding 
drug delivery and transport through complex 3D tissues, as well as development of 
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Transport of Nanoparticles  
in 3D Cellular Spheroid Culture  
 
2.1 Abstract 
As nanotechnology has been developing emergently for drug development, 
understanding transport of nanoparticles (NP) in dense tissues is essential for 
biomedical imaging and drug delivery using these agents. Compared to animal 
studies and traditional Petri dish cell cultures, three-dimensional (3D) tissue 
replicas approach the complexity of the actual organs and enable high temporal and 
spatial resolution of the NP permeation.  We investigated diffusional transport of 
NPs generally investigated as nanomedicines such as carbon nanotubes (CNTs) and 
26 
 
gold nanoparticles (AuNPs) in highly uniform spheroids of hepatocellular 
carcinoma derived by 3D cell culture in Inverted Colloidal Crystal (ICC) scaffolds. 
It was found that apparent diffusion coefficients of CNTs in these tissue replicas 
are extremely high and comparable to diffusion rates of similarly charged small 
molecules whereas AuNPs only accumulates on the surface of the tissue replicas in 
spite of the aspect-ratio difference. Moreover, diffusivity of CNTs in tissues is 
enhanced after functionalization with targeting ligand, transforming growth factor 
(TGFβ1). The finding in this chapter shows the feasibility of 3D cell culture testing 
for nanomedicine and the result also indicate nanotubes and potentially similar 
nanostructures are capable of fast and deep diffusion within the dense tissue for 
anticancer treatment such as solid tumor.  
 
2.2 Introduction 
Nanoparticles (NPs), such as polymeric nanocapsules, metallic nanorods 
(NRs) and carbon nanotubes (CNTs) have emerged as potent nanomedicine for 
drug delivery and cancer imaging1–3. Their unique optical and chemical properties 
originating from quantum confinement promisingly enhanced the therapy and 
diagnostics of many diseases4–8. There are many advantages of NPs as 
nanomedicine compared to the traditional methods of therapeutics and diagnostics, 
which include the prospects of functionalization with multiple targeting ligands, 
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synergistic effect of multiple drugs delivered in the same cargo, long clearance 
times, and enhanced permeability and retention effect for cancer treatment. 
Therefore, it prompted tremendous efforts on the targeting efficiency of NPs to 
specific cells, circulation in blood, and distribution among organs 9,10–12. 
However, little is known about their transport within the organs following 
transvascular delivery or locally injection that affects both the safety and efficacy 
of NPs as imaging and therapeutic agents. Understanding the transport processes 
for NPs within tissues or organ has been often hindered by lack of adequate 
preclinical models. Most studies have relied on analysis of cells grown in two-
dimensional (2D) cell culture models13–15, but they do not have adequate 3D 
morphology to maintain their differentiated functions, as a result, fail to replicate 
diffusion conditions in tissues. A variety of data regarding the biodistribution of 
NPs in different animal models has been reported 15–17. Although the studies 
involving the dissection of animal organs followed by imaging improve the 
resolution of distribution maps, they are limited to static post-treatment results. In 
addition, it is difficult to extract the transport parameters from these studies, 
because they were mostly focused on toxicity and drug clearance. They are also 
expensive and laborious comparing to ex-vivo studies. Moreover, the animal data 
were obtained for different tumor models, therapeutic modalities, administration 
routes, doses, and quantification methods, in consequences, it is difficult to be 
generalized because of the varieties of animals and environmental conditions, as 
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well as the difference between animals and human. This results in mismatches of 
the therapeutic effect on human in clinical study. 18,19 
Meanwhile, lack of suitable imaging technology with sufficient temporal 
and spatial resolution in animal studies lead to the difficulty of real-time NP 
distribution maps within organs. The resolutions of real-time in vivo imaging 
methods such as magnetic20, X-ray21,22, and photoacoustic imaging23 are currently 
sub-millimeter, micrometers or even sub-micrometers, respectively. Currently 
spatial resolution of fluorescent imaging have mainly met the requirement for the 
diameter of NPs (sub-μm).24 However, this resolution trades off the imaging time 
and depth of tissue penetration in vivo. Hence, the difficulties regarding to 
integration of advanced optical microscopy techniques incorporated with animal 
studies have been aware of. The high cost of such studies also makes it difficult to 
justify the routes for various types of NPs with different size, shape, surface charge, 
targeting ligand, and loaded drug.  
Therefore, critical need of standardized and convenient testing platform is 
emerging. Ex-vivo 3D tissue cultures became an attractive tool for evaluation of the 
transport of NP as delivery or imaging agent in tissues or organs. They are not only 
able to provide the morphological environment in actual tissues comparing to 2D 
cell cultures, but also allow high resolution and high throughput study for NP 
transport within tissue or organ and they allow for real-time monitoring of the 
transport processes.  The most widely used 3D tissue models are the multicellular 
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spheroids25–27 and multilayer cell cultures28,29. Recently, they have been used for 
the evaluation of NPs, such as polystyrene beads30, liposomes31, and viral 
particles32. These studies showed that smaller particles can infiltrate spheroids more 
effectively than larger particles,30 while NPs with low charge were shown to 
penetrate to the central regions of the spheroids better than those with high 
charge31,33. Also, it was indicated that NP transport was improved by 
functionalization with extracellular matrix-destroying enzymes30. It was also 
demonstrated that spheroid cell cultures of hepatocytes for the toxicity evaluation 
of CdTe and AuNPs have better correlation with the animal data found in the 
literature than 2D cell culture models.34 
Following important qualitative observations made in the studies above, it 
is important to quantitatively describe the properties of NP transport based on the 
phenomenon. In previous reports, some classic laws of diffusion describing the 
permeation of particles in homogeneous media may be utilized to describe the 
observations whereas could not predict NP transport accurately in tissues.35,36,37 
This is due to the cooperative nature of their interactions with cell membranes, 
multiplicity of active transport processes, and entanglement of diffusion in different 
dimensions. The suitable and easily approached model incorporated with 
correspondent diffusion’s laws is required for the insight understanding of NP 
transport.  Such that, the central objective of this chapter is to establish the 
experimental and conceptual framework for quantitative evaluation of NP transport 
in the dense tissues by the 3D cellular spheroid culture model ex vivo. In order to 
30 
 
accomplish the objectives we utilized 3D cell cultures of liver carcinoma cells 
(HepG2, ATCC) in inverted colloidal crystals (ICC)28,38 that were proven to 
provide close replicas for many organs with respect to both morphology and 
biological functions34,38. They are uniquely suitable for the purpose of this work 
because the spheroids grown in ICCs provide can be highly controlled and uniform 
in diameter, greatly simplifying the mathematical description of transport processes. 
Moreover, ICC scaffolds are transparent and make real-time assessment of NP 
distribution possible. AuNPs and CNTs as promising candidate of nanomedicine 
have been studied in the following sections.  
2.3 Materials and Methods 
2.3.1 Fabrication of ICC Scaffolds 
We utilized ICC scaffolds to obtain the tumor-like HepG2 spheroids as 
described in previous work10; polyacrylamide hydrogel ICC scaffolds were 
prepared by utilizing colloidal crystals (CC) (Figure 2.1a) as templates. To control 
the pore sizes of scaffolds, we use uniform glass beads in diameter of 170μm for 
penetration study. 3D structure of CC with high connection can be achieved by 
annealing at 680°C for 3 hours, following by being transferred into ICC geometry 
high porosity. ICC scaffolds with uniform porous structure (Figure 2.1b) facilitate 




Figure 2.1 SEM images of dehydrated hydrogel ICC scaffolds (b) created by 
dissolving beads template (a) from hydrogel matrix. Pore diameter was shrunk 
during the dehydration process of SEM preparation. Scale bars: 300µm (a, b). 
 
2.3.2 Cell and Spheroid Culture 
Human hepatocellular carcinoma cells (HepG2, ATCC) were maintained 
with Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% fetal 
bovine serum (FBS) and 1% Penicillin–Streptomycin. All the medium was filtered 
using 0.22μm SteriCup filter assembly (Millipore, USA) and stored at 4 °C for no 





Figure 2.2 SEM images of (a) dehydrated hydrogel ICC scaffolds cultured with 
cellular spheroids. (b) SEM images of a mature spheroid in an ICC scaffold 
cultured for 5 days. Maturation of the spheroid is accompanied with formation of a 
layer of extracellular matrix on its surface and individual cells become difficult to 
distinguish. Scale bars: 400µm (a) and 50µm (b). 
 
To form tissue-like cellular spheroids in ICC scaffold, 500,000 cells in a 
25μl of dense cell suspension (2x107 cells/ml) was dropped on top of dehydrated 
hydrogel ICC scaffold, followed by adding 975μl of media gently. Total culture 
volume was maintained at 1000μl in 96-well plates, with media change every two 
days. Nearly perfectly mono-dispersed spheroids in average diameter of 150 µm 
were observed in high yield after 5 days culture. (Figure 2.2a) Magnified image 
(Figure 2.2b) indicated structural features including the development of an 
extracellular matrix coating the membrane surface as well as abnormal bile 





2.3.3 Biocompatibility of CNTs   
CNTs are considered to be fairly biocompatible generally39,40.  Because 
toxicity data for 2D vs. 3D assays can be substantially different,40 we decided to 
initially carry out two standard live/dead cell viability assays which consisted of 
calcein AM and ethidium homodimer (EthD-1) (Figure 2.3a-d) addressing plasma 
membrane  integrity and esterase activity. Both assays indicated that the HepG2 
cells of spheroids proliferate normally in contact with medium containing as much 
as 1 mg/mL CNTs.  As the concentration was increased to 2 mg/mL, the cell 
viability decrease. The CNTs in spheroid 3D culture shows better biocompatibility 
than similar toxicity thresholds reported in 2D cultures.40 Therefore, we chose the 
concentration of CNTs at 0.5 mg/mL for the following permeation studies. 
Additional test WST-1 assay (Figure 2.3e) at this concentration was used to re-
verify cellular proliferation, viability, and cytotoxicity, based on the reduction of 
tetrazolium salt to formazan by electron transport across the plasma membrane of 
dividing cells. It indicated that the viability of CNT-treated cells is identical within 





Figure 2.3 Confocal images of live/dead cell viability assay (LIVE/DEAD 
Viability/Cytotoxicity Kit, Invitrogen, US) of HepG2 cells in spheroids cultured for 
3 days in medium containing (a, control) 0, (b), 0.5, (c) 1, and (d) 2 mg/mL CNTs 
in the culture medium (Eagle’s Minimum Essential Medium (EMEM) 
supplemented with 10% Fetal Bovine Serum (FBS) and 1% Penicillin–
Streptomycin (ATCC)). (e) WST-1 assay for HepG2 spheroids cultured with 0.5 








2.3.4 Labeling of CNTs with Fluorescence and Targeting Ligands 
To observe CNTs inside the 3D tumor tissue model under the confocal 
microscopes, we labeled CNTs (P3, Carbon Solution, Inc.) with fluorescence 
(Fluorescein isothiocyanate isomer I) by cross-linker, 1-ehyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), to make CNTs have an emission of 
wavelength at 595 nm. The oxidized CNTs were reacted with hexamethylene 
diamine in the presence of EDC to afford a linker between the CNT and the 
subsequent fluorescent probe. In brief, 2 mg of oxidized CNTs were mixed with 5 
mg hexamethylenediamine and 1 mg EDC in 4ml 0.1M MES buffer (pH 6.0). The 
mixed solution was stirred at room temperature for 2 h. The oxidized CNTs bonded 
with hexamethylenediamine (CNT–CONH–(CH2)6NH2) were obtained by 
centrifuging the mixture at 10,000 rpm for 20 min. 4mg of obtained CNTs were 
dissolved in 200µl dimethylformamide (DMF). N, N-diisopropylethylamine (DIEA, 
2μL, 11.5μmol) and a solution of fluorescein isothiocyanate (FITC, 2.5mg, 6.4μmol) 
in 200μL of DMF were added. The reaction mixture was stirred for 4h at room 
temperature. The solvent was evaporated and the FITC-labeled CNTs were 
precipitated several times from methanol/diethyl ether and dried under vacuum.41,42  
2.3.5 Functionalized CNTs with Targeting Ligands 
CNTs were functionalized by covalent attachment of the targeting ligand. 
The CNTs with targeting ligands, transforming growth factor β1 (TGFβ1, Santa 
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Cruz Biotechnology, Inc.), were prepared using the following procedure which was 
simplified from the previous method. In short, 0.5mg oxidized CNTs (0.5 mg/mL) 
were dispersed in phosphate buffered saline (PBS) by sonication for 5 min followed 
by incubation with 8 mg EDC for 1 min at room temperature, after which samples 
were immediately vortexed. Next, TGFβ1 5µg in 50µl PBS and FITC (Fluorescein 
isothiocyanate isomer I) (2μg in 20µl of DMF) were added together, and the 
resulting mixture was allowed to react for an additional 2 h at 37 °C in a rotator 
rocker. These samples were then centrifuged at 1300 rpm for 20 min for 3 times to 
remove unbound antibodies and excessed FITC in Centricon YM-50 tubes 
(Millipore Corporation, MA, USA) and the resulting CNT-TGFβ1-FITC were 
suspended in 1 mL serum-free Eagle’s Minimum Essential Medium (EMEM) and 
used immediately.42 
2.3.6 Labeling of AuNPs with Fluorescent Polyethylene Glycol  
To functionalize the surface of AuNPs with fluorescence, 2mg/ml AuNP 
solution with three aspect-ratios in water is added with 2mg/ml fluorescent 
polyethylene glycol (SH-PEG-FITC, MW 5K, Nanocs Inc.), then the mixture is 
kept at room temperature overnight. The mixture is centrifuged at 5000-8000 





2.3.7 Molecular Weight of CNTs and Their Derivatives 
According to TEM images (Figure 2.4a), the CNTs had an average 
diameter of 1.2 nm and a length of 1,000 nm. Therefore, it was calculated that 40 
carbon atoms ((1.55 nm/0.245 nm) × (3.1414) × (2 carbon atoms)) are around the 
circumference. For every 0.283 nm length, there are 124 carbon atoms (4 × 40 
carbons), namely, 6,790,106 amu ((1000nm/0.283nm) × (160) × (12.01)). So the 
calculated molecular weight of CNT is 6.79 × 106 Da. Fluorescent CNTs bearing, 
on average, 1-3 atomic % of FITC, which is 1246 Da (0.02 x 160 x 389.38 per tube) 
heavier than original CNTs as purchased (Figure 2.4b). To determine how many 
antibodies are there on targeted CNT (CNT-TGFβ1-FITC), TEM images were 
captured and analyzed statistically and it was found 2~3 antibodies on each CNT 
in average, which agreed with theoretical number 2.97 ± 0.32 (3.80 × 10-20 g, 
(TGFβ1 MW 23000 Da × 1.66 × 10−24
 
g)). As a result, the theoretical molecular 
weight of CNT-TGFβ1-FITC is 6.87 × 106 Da. The actual molecular weight was 
verified by TEM images and determined to be 6.84 × 106 Da due to loss during 




Figure 2.4 TEM images of CNT (a), CNT-FITC (b), and CNT-TGFβ1-FITC (c). 
 
2.3.8 Theoretical Diffusion Coefficients of CNTs, FITC, TGFβ1 and Rhodamine B 
Theoretical diffusion coefficient D0 for spherical particle related to the 
temperature T and the friction coefficient 𝒇𝟎 can be calculated using the Stokes 
equation: 
𝑫𝟎 =  
𝒌𝒃 𝑻
𝒇𝟎
                                            Eq 2.1 
𝒇𝟎 = 𝟔𝝅𝜼𝑳𝟎                                       Eq 2.2 
where kb = 1.38 × 10
-20 m2·g/(s2·K), T = 293 K, η = viscosity of the solute, L0 = radius 
of a spherical particle or molecule with a volume equal to the volume of a rod-like 
particle or molecule. Frictional coefficient is determined by the viscosity of the 
media and diameter of the spherical particle.  
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The frictional coefficient fn of a non-spherical particle (rod or tube) is 
usually larger than that of a spherical one of the same volume because there is a 
larger surface area in contact with the solvent. Therefore, assuming Dn is the 
theoretical diffusion coefficient for non-spherical particles, when the particle is 
non-spherical such as a CNT, we could suppose a CNT as a rod-like particle which 
has a length a = 1000 nm/2 and radius b = 1.55nm/2 (Carbon Solution, Inc. Data 
sheet.). Its volume is given by the formula: 
𝑽𝒓𝒐𝒅 = 𝟐𝝅𝒂𝒃
𝟐                                        Eq 2.3 
The aspect ratio P can be defined as: P = a/b = 645.2. The frictional coefficient of 
a rod-like particle can be calculated as (6) 






                                    Eq 2.4 






                                             Eq 2.5 
f0 is calculated to be 7.52 × 10
-4 g/s in tumor tissue (η = 5.2 ± 2.5 Pa·s).47   
𝒇𝟎 = 𝟔𝝅𝜼𝑹𝟎 = 6 × 𝝅 × 5.2 × 10
3 g/(s·m) × 7.67 m × 10-9 = 7.52 × 10-4 g/s 
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D0 = (1.38 × 10
-16 gcm2/s2 × 293 K)/7.52 × 10-4 = 5.4 × 10-15 m2/s 
Thus fn equals 9.91 × 10
-5 g/s for tumor tissue according to equation (4). Theoretical 
Dn value of rod-shaped CNTs in tumor tissue is determined to be 5.7 × 10
-16 m2/s. 
To calculate the theoretical diffusion coefficients of TGFβ1, FITC, and 
Rhodamine B (RhB), it was assumed that these molecules were rod-shaped, where 
the longest distance in the molecular structure is represented by a and the shortest 
by b. The molecular structure and distance of TGFβ1 between atoms were reported 
in a previous study1 (Figure 2.5 a). Moreover, a and b of FITC and Rhodamine 
were analyzed and measured using software Spartan 10 (Figures 2.5 b, c). P will 
be calculated based on values of a and b for each type of molecule.  
 
Figure 2.5 The molecular structure and distance of TGFβ11 (a), FITC (b) and RhB 
(c) where a is the longest distance between atoms in one structure, and b is the 
radius of stimulated molecular structure. Spheres (atoms) of (b) and (c): Grey-C; 









 =   √
𝟑 × 𝟏. 𝟔𝟎𝟕 × 𝟏. 𝟏𝟓𝟐𝟐
𝟐
𝟑
 =   6.027 𝑛𝑚                                            
𝒇𝟎 = 𝟔𝝅𝜼𝑳𝟎 = 𝟔 × 𝝅 × 5.2 × 10
3 g/(s·m) × 6.027 × 10-9 m = 5.9 × 10-4 g/s 
𝑫𝟎 =  
𝒌𝒃 𝑻
𝒇𝟎
 = 1.38 × 10-16 g∙cm2/s2 × 293 K /5.9 × 10-4g/s = 6.9 × 10-15 m2/s 












  = 7.1 × 10-4 g/s  
𝑫𝒏 =  
𝒌𝒃 𝑻
𝒇𝒏
 = 1.38 × 10-16 g∙cm2/s2 × 293 K /7.1 × 10-4 g/s = 5.7 × 10-15 m2/s 





 =   √
3 × 0.945 × 0.46342
2
𝟑
 =  0.673 nm                                            
𝒇𝟎 = 𝟔𝝅𝜼𝑳𝟎 = 6 × 𝝅 × 5.2 × 10
3 g/(s·m) × 0.673 × 10-9 m = 6.6 × 10-5 g/s 
𝑫𝟎 =  
𝒌𝒃 𝑻
𝒇𝟎
 =1.38 × 10-16 g∙cm2/s2 K-1 × 293 K /6.6 × 10-5 g/s = 6.1 × 10-14 m2/s 












 = 9.91 × 10-5 g/s  
𝑫𝒏 =  
𝒌𝒃 𝑻
𝒇𝑛








 =   √
3 × 1.607 × 1.1522
2
3
 = 1.473 𝑛𝑚                                            
𝒇𝟎 = 𝟔𝝅𝜼𝑳𝟎 = 6 × 𝝅 × 5.2 × 10
3 g/(s·m) × 1.473 m 10-9 = 1.45×10-4 g/s 
𝑫𝟎 =  
𝒌𝒃 𝑻
𝒇𝟎
 =1.38 × 10-16 g∙cm2/s2 K-1 × 293K /1.45 × 10-4 g/s = 2.8 × 10-14 m2/s 












  = 2.2 × 10-4 g/s  
𝑫𝒏 =  
𝒌𝒃 𝑻
𝒇𝒏
 = 1.38 × 10-16g∙cm2/s2 K-1 × 293K /2.2 × 10-4 g/s = 1.8 × 10-14 m2/s 
𝑫𝟎 is the diffusion coefficient for a spherical shape ;  
𝑫𝒏 is the diffusion coefficient for a rod shape.  
 
2.3.9 Imaging Methods for NP Transport Study 
Confocal Microscopy. Stained with live/dead assay, live cells are green, 
while dead cells show red. In live/dead assay test, contracted HepG2 spheroids in 
ICC scaffolds were treated with 0.5 mg/mL, 1mg/mL, and 2 mg/mL CNTs in 
culture medium for 2 hours, with non-treated spheroids (CNT free) used as the 
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control. To be observed by Confocal Microscopy during penetration, HepG2 cells 
in spheroids in scaffolds were pre-labeled by orange-colored CMTMR (Invitrogen, 
CA); CNTs labeled with FITC were added into scaffolds under the microscope. 
After 20 min, observation of the penetration process was initiated through a 
confocal microscope and 36 z-stack images range from top (0µm) to bottom 
(~150µm) were taken of the whole spheroid every 20 min. The process of FITC 
and RhB molecules penetration into spheroids was observed in the same way as the 
CNTs. 
Surface Enhanced Raman Scattering (SERS) Spectroscopy. The inelastic 
scattered radiation was collected with a Renishaw Invia Reflex system equipped 
with two dimensional Peltier charge coupled device (CCD) detectors and a Leica 
confocal microscope. The spectrograph uses high resolution gratings with 
additional band-pass filter optics.  The laser line focused onto the spheroid in 
scaffold with backscattering geometry using either 100× objective providing 
scattering areas of ~0.5 µm for mapping, or a macrosampling 90° objective adaptor 






2.4 Results and Discussion  
3D cell cultures in ICC scaffolds10 are used in this study to investigate 
AuNP and CNT permeation through cellular spheroids formed by hepatocellular 
carcinoma cells.  The transport process was monitored and recorded in real time by 
available imaging methods such as confocal microscope and SERS Spectroscopy. 
2.4.1 AuNP Transport in HepG2 Cellular Spheroid 
SERS, as a potential imaging method, was utilized first to observe AuNPs. 
However, it was found damaging the live cells during the focusing process within 
10 min. The alternative imaging AuNPs were modified with fluorescent thiol-PEG-
FITC for observation within cellular spheroids. HepG2 cells were labeled by 
CellTracker™ CMRA (Invitrogen, US) with orange-red luminescence.  Gold 
nanospheres, nanoshells with multiple sizes and gold nanorods with different aspect 
ratios of 1:2 and 1:3 in diameter of 30nm were observed under the confocal 
microscope and SERS. Unfortunately, AuNPs in general were opt to accumulate 




Figure 2.6 Sliced confocal images of HepG2 spheroids after 90 min exposure to (a) 
AuNR-FITC (Green) with dimension of 30:60nm. HepG2 cells in spheroids were 
stained red (CMTPX) before spheroid formation for images. (b) 3D re-construction 
image can clearly show the inefficient penetration of AuNPs on the surface of the 
cellular spheroid. 
 
2.4.2 Diffusion of CNTs in Cellular Spheroid 
To observe CNTs using standard confocal microscopes inside the spheroids, 
we labeled them with standard luminescent tag FITC. Transforming growth factor 
β1 (TGFβ1) was chosen as the targeting ligand because TGFβ receptors are present 
in HepG2 cells14 and up-regulated in many cancers. The nanotubes without 
targeting ligand are referred to as CNT-FITC while the ones carrying both TGFβ1 
and FITC are referred to as CNT-TGFβ1-FITC. The total load of the TGFβ1 per 
CNT was 1.13×10−17 g which amounts to 2.6±0.3 molecules of the targeting ligand 
on an average nanotube. The average molecular weight (Mr) of CNT-TGFβ1-FITC 
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was 6.84×106 Da.  It can be compared to Mr = 6.79 × 106 Da of the CNT-FITC that 
are 5.83±0.74 ×104 Da lighter. Electrokinetic zeta-potential (ζ) of CNT-TGFβ1-
FITC and CNT-FITC were -8.4±0.306 mV and -0.01±0.001 mV, respectively 
(Table 2.1).  
Table 2.1 Zeta potential or Molecular Charge of CNTs and Small Molecules 
 Zeta potential or Molecular Charge 
 (in PBS pH=7.4) 
CNT-FITC-TGFβ1 -8.4±0.31 mV 
CNT-FITC -0.01±0.001 mV 







Figure 2.7 Confocal imaging and modeling of diffusion profiles in HepG2 
spheroids after 20 min exposure to fluorescent penetrants. Sliced confocal images 
of HepG2 spheroids after 20 min exposure (b) CNT-FITC and (d) FITC (8.7 ×10-
5mg/ml). HepG2 cells in spheroids were stained red (CMTPX) before spheroid 
formation for images. CNT-FITC and FITC have green fluorescence. CNTs and 
free molecules have green fluorescence in (a and c); the penetration depth is defined 
at the peak of fluorescent intensity. HepG2 cells in spheroids were stained red 




To visualize green-fluorescing CNT-FITC and CNT-TGFβ1-FITC on the 
background of tissue spheroids, HepG2 cells were labeled by CellTracker™ 
CMRA (Invitrogen, US) with orange-red luminescence. In some cases, HepG2 
cells in spheroids were stained by CellTracker™ Red CMTPX dye or 5-
chloromethylfluorescein diacetate (CMFDA) (Life Technologies, US) with red and 
green luminescence, respectively.  Z-stack images of multiple spheroids (Figure 
2.7a, c) were captured at 20, 40, 60, 80, 100, and 120 minutes after addition of 
permeants to the cell culture.  FITC and TGFβ1 molecules were also observed as 
control (Figure 2.7b, d). 
Apparent diffusion coefficients, Da, reflecting the experimentally 
observable rate of their transport were obtained for FITC, Rhodamine B (RhB), 
TGFβ1, CNT-FITC, and CNT-TGFβ1-FITC by fitting the progression of 
experimental diffusion profiles with the Second Fick’s law (Table 2.2) using our 
own code. 41-45  











)                                    Eq 2.6                             
where C = concentration, t = time, r = distance/radius, 𝑫𝒂 = diffusion coefficient. 
We assumed that the diffusing substance moves into the center of the spheroid and 
the boundary at r = 0 is the surface of the spheroid:  
(i) C(0, t) =C0, t ≥ 0 (L is the mean diameter of 3D tumor tissue model);  
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(ii) C(R, t) = 0, t = 0; 
(iii) At r = d, ∂2C/∂t2 = 0 (d is the measure of penetration depth at a certain time 
point). Then we obtained the equation regarding the depth d and time t from  
 
d2=6π𝑫𝒂∙t                                             Eq 2.7 
 




Coefficient,  Da 










In our model of diffusion, the tumor tissue-like spheroid is considered as a 
sphere of radius L. Under the boundary conditions of the experiments performed, 
this depth of highest concentration in the diffusion front was the measure of 
penetration depth d. Firstly, according to the z-stack and cross-section images, 
depth d in equation (7) represents how far fluorescence reached inside the spheroid, 
where the fluorescence represents FITC, RhB, and CNTs or their derivatives. These 
data of depth d and time t abstracted from images will be substituted into equation 
2.7 and certain values of 𝑫𝒆𝒙 will be fit to find the best value of D that minimizes 
the error by statistically analysis of Mathematica 8.0 (See Appendix).  
The values Da for FITC and RhB indicate that diffusion of these small 
molecules in cellular spheroids grown in ICC scaffolds are similar to those 
observed previously in solid tissues ;15 these data provided us useful benchmarks 
and validated our methods. Concentration profiles inside the spheroids were 
derived from the fluorescent intensity of the permeants (Figure 2.8).  As anticipated 
from the previous studies,3, 16 diffusivity of the small luminescent molecules in 
tissue model is strongly dependent on charge, with Da = (5.9±0.3) ×10
-13 m2/s for 
RhB being considerably higher than Da = (1.6±0.3) ×10
-14 m2/s for FITC.  The 
positive charge of RhB is facilitated by electrostatic attraction to negatively charged 
cellular membranes.  We noticed that Da = (0.9±0.3) ×10
-14 m2/s of CNT-FITC is 
comparable to the diffusion coefficient of free FITC.  Note that the average 
molecular mass  Mr =6.79 × 106 Da of CNT-FITC is 1.7×104 larger than that of 
FITC with Mr = 389.4 Da. The startling closeness of diffusivity for these two 
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species contradicts known trends for diffusivity of permeants in gas, liquid, solid 
or gel. As such, diffusivity CNT-FITC predicted by Einstein-Stokes diffusion 
equation for rod-like particles is lower by almost two orders of magnitude that 
experimental values (Table 2.3).   
 
 
Figure 2.8 Confocal imaging and modeling of diffusion profiles in HepG2 
spheroids after 20 min exposure to fluorescent penetrants. (a) and (b) are calculated 
diffusion profile of  CNT-TGFβ1-FITC and RhB, which compare to (c) and (d), 
permeation profiles of  CNT-TGFβ1-FITC and RhB at central focal plane of the 
spheroid with its 3D surface plot; (e, f) are the 3D surface plot of (c, d); H-axis 





Table 2.3 Stokes-Einstein diffusion coefficients of CNTs and small molecules 
  
Stokes-Einstein 
Value of D 
rod-like shape 
Stokes-Einstein 
Value of D 
spherical shape 
   (m2/s in tissue)  (m2/s in tissue) 
CNT-FITC-TGFβ1 5.7×10-16 5.4×10-15 
CNT-FITC 5.7×10-16 5.4×10-15 
TGFβ1 5.7×10-15 6.9×10-15 
Rhodamine 1.8×10-14 2.8×10-14 
FITC 4.1×10-14 6.1×10-14 
 
Although approximate, the Einstein-Stokes diffusion equation correctly 
predicts the increased friction coefficients between permeants and fluid for rod 
shaped particles and typically yields a reasonably good match with experimental 
values.  Note also that both FITC and CNT-FITC have negative charge and 
“acceleration” of nanotube transport cannot be attributed solely to favorable 
electrostatic interactions with cellular membranes. Furthermore, Da of CNT-
TGFβ1-FITC is equal to (1.5±0.2) ×10-13 m2/s markedly exceeding the diffusion 
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coefficients of both CNT-FITC and FITC, despite even greater Mr = 6.84 × 106 Da.  
Note that diffusion of CNTs in blood, lymph, and bile17 with Da equal to 
(0.59±0.18)×10-14 m2/s,  (1.45±0.65)×10-14 m2/s, and (0.9±0.2)×10-14 m2/s, 
respectively, is considerably slower17, which is also counterintuitive considering 
that these tissues are liquid.  Experimental observations of CNT transport in dense 
bacterial biofilms18 and glomerular membranes19 confirm that nanotube transports 
in dense bio logical media is anomalous although might have been attributed to 
different causes.  
The unexpectedly high diffusion coefficients on CNTs in dense tissues were 
puzzling and we decided to verify the permeation of CNT-TGFβ1-FITC through 
the 3D tissue models using microscopy techniques to avoid potential artifacts 
associated, with, for instance, the slow detachment of FITC from nanotubes.  After 
20 min of exposure of spheroids to CNTs-TGFβ1-FITC, the nanotubes were found 
to be imbedded in the cellular mass (Figure 2.9a-c). The comparable scanning 
electron microscopy images of the spheroids prior to exposure to nanotube 
dispersion can be found in Figure 2.2. To verify permeation of CNTs to the central 
part of the spheroid, we also carried out histological sectioning of ICC scaffolds. 
CNTs can be found in SEM images of the slices of the spheroids obtained at middle 
focal plane ~38µm from the spheroid’s surface (Figure 2.9 e-f) which agrees with 




Figure 2.9 SEM images of HepG2 spheroids after exposure to CNT-TGFβ-FITC 
for 20 mins (a-c). The surface of the spheroid at different magnification.  CNTs in 
all the images could not be washed off without physical destruction of the tissue 
model that indicated their penetration inside the cellular mass.  (d) Histological 
sections of HepG2 cell cultures in ICC scaffolds with CNTs oriented predominantly 













The method described in this work enables accurate and systematically 
evaluation of the different modes of transport of CNTs and CNT-based drug 
delivery systems necessary for comprehensive pharmacokinetic models.30 In the 
same manner, in-vitro 3D cell cultures with ICC scaffolds, which can easily apply 
to other molecules/nanoscale carriers, offers possibility for simple comparative 
studies between different drug carriers in the absence of complicating factors such 
as pharmacokinetics and metabolism.31  Our results also indicates that it is 
important to design drug delivery systems such that they strike a balance between 
efficient diffusion and cellular affinity, ensuring that the therapeutic will transport 
deep within the tumor and accumulate in quantities sufficient to elicit a therapeutic 
effect. In the future study, incorporation of the physical and chemical parameters 
such as fluid flow and shear force into the 3D tissue model could be done to provide 
deeper insight into the effects of CNT-tissue on transport efficiency. Certainly, in 
addition to in-vitro study, the corresponding data from in-vivo studies and clinical 
evidence will be needed to standardize the data obtained from the 3D model for 
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Appendix 2.1 Mathematica Code for Data Processing (Example: one set of data 





















Transport of Carbon Nanotubes in Cellular Spheroid: 
A Simulation Study 
 
3.1 Abstract 
Anomalously fast diffusion of targeted carbon nanotubes (CNTs) has been 
investigated within cellular spheroid as classic diffusion in previous chapter. 
However, why CNTs modified with targeting ligand diffuse faster is still obscure. 
In this chapter, we hypothesized that in the dense tissue/tumor with high chance of 
cellular membrane binding, anomalous diffusion occurs due to surface diffusion on 
the membrane, in which the mean-square displacement is not only proportional to 
an integral power of time in three dimensional space. The results from cell-CNT 
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interaction in vitro and diffusion coefficient data fitting in equation of two-phase 
diffusion proved that the fast diffusion of CNTs is the consequence of the planar 
diffusion along cellular membranes, which reduced effective dimensionality of 
diffusional space. Furthermore, to better understand the transport properties of CNT 
in dense tissue, we discussed simulated models incorporated with binding and 
surface diffusion in which immobile cells in spheroid are represented by obstacles 
that bind diffusing CNT in nearest-neighbor sites. Random Walks in two phases 
are utilized in the simulation. The result indicated anomalous diffusion of CNTs is 
associated with affinity of CNT with cell membrane regarding to distribution 
coefficient K of the simulated CNT between lipids and interstitial liquid at 
equilibrium conditions. In addition, it is highly dependent on the void volume (𝟇 
and 𝒂𝒗) of the simulated structure which shall be related to specific tissue structure. 
   
3.2 Introduction 
Carbon nanotubes (CNTs) have been considered as a promising nano-sized 
pharmaceutical agent for drug delivery and imaging application. 1, 2, 3 The use of 
CNTs as deliver cargo to deep tissue/tumor has attracted considerable interest. It 
has been shown in recent study that apparent diffusion coefficients of targeted 
CNTs in three-dimensional (3D) cell culture in vitro are anomalously high and 
comparable to diffusion rates of similarly charged molecules with much lower 
molecular weights4.  Hence, although diffusion of CNTs in dense tissue have not 
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yet been used in vivo, nanotubes are promising as anticancer agents for fast and 
deep permeation into the hypoxia region of tissue/tumor.5 Understanding of their 
transport through complex 3D tissues both fundamentally and practically is an 
important consideration for pharmacodynamics analysis to validate drug doses and 
administration regimens required to achieve desired therapeutic effects. 6,7  
The current studies of nano-sized agent transport are focused on 
biodistribution or local accumulation experimentally, of which the data were 
obtained with widely different protocols due to variety of animals, drug doses, and 
evaluation methods.8  Therefore, numerous effort was brought to measure or 
simulate diffusivity of these agents in homogeneous physiological media according 
to the rules of unobstructed free diffusion.9 Such that, the mean-square 
displacement of the diffusing particle is proportional to time as in Brownian 
diffusion. Furthermore, if CNTs are used as local injection into dense tissue or 
tumor focus, in classical model it is always considered intercellular diffusion and 
CNT-cell interaction including binding and internalization. While in dense 
tissue/tumor, obstruction by or interaction with the cells may lead to anomalous 
diffusion, in which diffusion is usually considered being hindered.10,11,12 As a result, 
in the obstructed space, CNTs should have diffused slower than free diffusion. 
However, the experimental results have indicated that diffusivity diffusion of 
targeted CNTs enhanced in dense tissue structure. 
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The fundamental mechanism of enhanced targeted CNT transport is still 
unclear. For instance, how does enhanced CNTs diffusion occur in dense tissue 
with cellular obstructions? Does cellular membrane diffusion influence anomalous 
diffusion in dense tissue under the equilibrium state of binding/unbinding? What 
feature(s) is essential for CNT diffusivity? In this chapter, we hypothesize that in 
the dense tissue/tumor with high chance of cellular membrane binding, anomalous 
diffusion occurs due to surface diffusion on the membrane, in which the mean-
square displacement is not only proportional to an integral power of time in three 
dimensional space. Cell-CNT interaction was examined by 2D cell culture in vitro 
to support the assumption of CNT binding/unbinding equilibrium in the 
environment. Diffusion coefficient data in previous study was extracted for data 
fitting in equation of two-phase diffusion. The results proved that the fast diffusion 
of CNTs is the consequence of the planar diffusion along cellular membranes, 
which reduced effective dimensionality of diffusional space.  
The effect of planar diffusion on CNT transport was highly related to the 
affinity of permeant and volume fraction of the dense tissue. In order to understand 
how these factors associate with apparent diffusion coefficient of CNTs, the 
computational models with conditioned cellular structure and permeates was built 
according to the experimental microenvironment of dense tumor tissue. Simulated 
cellular spheroid structure was created by inert designed spheres according to 
experimental model. The computational Monte-Carlo sampling and analysis of 
conditioned microenvironment are coupled with the standardized and uniform-
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sized liver tumor spheroids culture model in Inverted Colloidal Crystal (ICC) 
scaffolds in vitro for experimental study in Chapter 2 and provided identification 
or validation of predictive drug transport and efficacy. The simulation result 
presented here shows the affinity of CNTs with cellular membrane (K) is essential 
for the effective diffusivity in dense tissue. In addition, both actual apparent 
diffusion in spheroid culture and simulated displacement in two-phase diffusion 
model, apparent diffusivity is highly depending on the interstitial space and cellular 
structure such as void fraction (𝟇).  
 
3.3 Materials and Methods 
3.3.1 Cellular Spheroid Cultured in ICC Scaffold 
Realistic models of this study, Cellular spheroids, were formed by liver 
hepatocellular carcinoma cells (HepG2, ATCC, VA) in ICC scaffold. 4,12 The 
geometry of ICC scaffold is shown as hexagonally packed uniform spherical 
cavities connected to each other, while material of the scaffold is made of 
polyacrylamide. 4,12  As a result, mono-dispersed spheroids are nearly perfectly 
formed by seeding a 25 μl of dense cell suspension (2×107 cells/ml) and culturing 
for 5 days (Figure 3.1a). The cells were stained with Viability/Cytotoxicity assay 
(Life Technologies, US) to indicate live (green-fluorescent) from dead cells (red-
fluorescent) by simultaneously staining with calcein-AM to indicate intracellular 
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esterase activity and ethidium homodimer-1. Mature spheroids include the 
extracellular matrix coating on their surface (Figure 3.1b). The final realistic model 




Figure 3.1 Cellular Spheroids in realistic model. (a) Confocal microscope image 
of uniform cellular spheroids formed in ICC scaffold: cells were stained with 
Viability/Cytotoxicity assay where live cells are green fluorescent and dead cells 
are red fluorescent. (b) Characterization image of mature cellular spheroid taken by 
SEM shows extracellular matrix covered on the surface.  
 
3.3.2 Simulated Cellular Spheroid Structure  
To simulate the transport of CNTs in the practical model, the computational 
model of cellular spheroid is built in a range of 142 µm referring to the average 
diamter of realistic model in x, y and z axises, and the model consists of spheres as 
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individual cells in the grid (Figure 3.2a). The diameter of sphere corresponds to 
average value of indiviual HepG2 cell as 9µm.13  The minimum distance between 
spheres is coresponding to the interstitial space with diameter of 1.34µm9. 
 
 
Figure 3.2 Computational model of cellular spheroid is built in Matlab with spheres 
as individual cells (a). Transport of CNTs is simulated as in the scheme (b) where 
nanotubes as black dots in the grid undergo surface diffusion on the membrane and 
3D diffusion in the interstitial space. 
 
 
As a result, this simulated model contained 512 cells with the void fraction 
of 56.4%, within the range of medical observation of 50%-80%.14 The scheme 
(Figure 3.2b) represents the model for simulations of CNT diffusion in interstitial 
space and/or membrane surface, as well as its interaction with cell membrane. The 
CNTs undergo 3D diffusion as 3D random walk in a cubic volume, and bind 
reversibly (with the kinetic equilibrium constants K) to one of the volume 
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boundaries, representing the cell membrane. The bound CNT is allowed to be 
mobile as planar diffusion as 2D random walk.  
 
 
3.3.3 Monte-Carlo Simulations of CNT Diffusion by Random Walks 
In this simulation, an apparent diffusivity Da can be described in terms of 
the diffusivities associated with an equivalent capillary and of tortuosity factors for 
the void and surface phases. These properties are determined by the model structure 
built in simulation. Based on assumptions of association-dissociation equilibrium 
(K)15 in the system 






 𝒂𝒗𝑲                                 Eq 3.1 
where Di and Dmem are interstitial phase diffusivity and cell membrane surface 
diffusivity, in equivalent capillaries. The terms 𝞽𝒊 and 𝞽𝒎𝒆𝒎 denote the void and 
surface tortuosities, defined as the length of the equivalent capillary required in 
order to describe effective diffusivities in the void and surface phases, respectively. 
These two factors depend on the structure in simulated obstructs. 𝟇 is void fraction 
of tumor. 𝒂𝒗 is volume ratio (cylinder layer-cell membrane to capillary-interstitial 
layer).  Therefore, transport of CNT within dense tissue can be described as 
interstitial and cell membrane surface two-phase diffusion within the structure 
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associated with 𝞽, 𝟇 and 𝒂𝒗. 
16,17 According to the practical diffusivity of CNTs in 




/s in plasma9 and Dmem = (2.3±0.7) µm
2
/s 13 
were used in the simulation.   
The diffusion was treated in terms of random walks, and the expected value 
of apparent diffusion coefficient Da was computed using a Monte–Carlo algorithm, 
Metropolis–Hastings algorithm, with an average step size determined by the 
diffusion coefficient Di and Dmem. CNTs are initially placed at the starting position 
within 10nm from the simulated tissue model. As a result, the nanotubes located in 
void space are allowed to move as described below. Each simulation monitors the 
cumulative mean squared displacement of a thousand CNTs, MSD, of 5.3µm2 /walk 
in interstitial space and 828 µm2/walk on the membrane with curvature based on 
assumptions of association-dissociation equilibrium (K).  Da is given by the 




                                     Eq 3.2 
in which t is the walking steps of random walks and representative of one second.  
3.3.4 Markov chain of the algorithm in CNT random walks 
The possible move in the Markov chain of this algorithm in the simulation 
was described as below (Figure 3.3): 
Start of point p0 at t0 is in intercellular space 
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i. go to position p1 at t1 and then go to p2 position at t2 in intercellular space. 
 ii/iv 
ii. go to position p1 reversibly bind to the membrane at t1 and then go to p2 
on the membrane at t2.  iii/iv 
iii. go to position p3 on the membrane at t3.  ii/iv 
iv. go to position p3 into intercellular space at t3.  ii/v 
v. go to position p1 at t1 and then go to p2 back into intercellular space at t2. 
where p0, p1, p2 and p3 are the positions in the grid at time t0, t1, t2 and t3. 
 
 
Figure 3.3 Flow chart of Markov chain by Metropolis–Hastings algorithm for 
random walks of CNTs. Transition probability of status is shown as W, associated 
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3.4 Result and Discussion 
The collected microscopy and calculation data in Chapter 2 indicate that 
biochemical interaction CNTs with the tissue model are likely to strongly alter their 
transport compared to purely Brownian diffusion.20  Let us now consider possible 
pathways of CNT transport in the cellular spheroids. CNTs can permeate through 
the interstitial space and across/along the cell membranes.7,21  In addition, the 
transport process is also influenced by the interaction of CNTs with extracellular 
matrix (ECM) and living cells, which is expected to affect their mobility in 
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tissues.22  The transport processes at the cellular interface include adsorption to the 
cellular membrane, surface diffusion, desorption from the cellular membrane, 
endocytosis, and exocytosis (Figure 3.4).  
 
 







3.4.1 Transport based on cell-CNT interaction 
The transport of CNTs in tissue can cumulatively be described by an 
equation  
                        
𝝏𝑪𝒆𝒙
𝝏𝒕 
= 𝛁 ∙ (𝑫𝒆𝒙 𝛁𝑪𝒆𝒙 − 𝒖𝑪𝒆𝒙) - R                                  Eq 3.3 
where the concentration of CNT in interstitial/extracellular space is Cex and u is 
convection coefficient.18 Dex is diffusion coefficient in the extracellular spaces, 
approximated as homogeneous aqueous media 19, 20.  Biological interactions of the 
CNTs with the ECM and cellular membrane including adsorption, surface diffusion, 
desorption, endocytosis, and exocytosis are represent by the reaction term R 21. 
Diffusion conditions specific for tissue model allow us to simplify Eq 3.3.  Firstly, 
ICC scaffolds prevent macroscopic fluid flow and, thus, convection term 𝒖Cex can 
be eliminated.  Secondly, within the 120 min of our experiment, exocytosis 
component of the term R of CNT has minimum effect on transport process as 
reported by Strano et al.19  The remaining components of R for CNTs-FITC and 
CNTs-TGFβ1-FITC can be evaluated in 2D cell culture.   
Previous studies showed that surface properties of CNTs have an effect on 
cell internalization and excretion of nanoparticles and molecules.22 To determine 
how the different surfaces of CNTs influenced their interactions with cell 
membranes and to quantify endocytosis component of R, we first blocked the 
energy-enabled membrane transport of cells for the CNTs and their derivatives with 
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FITC by treating the cells with sodium azide and 2-deoxyglucose. HepG2 cells 
were incubated with CNTs-FITC and CNTs-TGFβ1-FITC at both 4°C and 37°C 
for 1 hour. Statistically identical small amounts of CNTs-FITC and CNTs-TGFβ1-
FITC were internalized by cells for both experimental conditions (Figure 3.5-7).   
Subsequently, we carried out confocal fluorescence microscopy studies of 
their uptake and intracellular distribution in living cells without endocytosis 
(Figure 3.6). By analysis of confocal images, it was found that without endocytosis, 
CNTs and their derivatives can both penetrate into cells by direct insertion. When 
the temperature decreased, the lipid membrane become rigid and reduced the 
penetration amount of CNTs. Moreover, fewer CNTs with ligands penetrated into 
cells through transient pores than regular ones. With blockage of an energy source 
and thus the endocytosis, the internalization of CNTs is theoretically through lipid-
membrane fusion only23. The results shows internalization of CNT-TGFβ1-FITC 
were lower than that of CNT-FITC. Meanwhile, the ratio of endocytosis at normal 
status was measured by staining and counting endosomes in cells. The images 
(Figure 3.7) implicated CNT with targeting ligand were internalized more by 
endocytosis whereas CNT-FITC interacted with cells by a lipid-assisted 
mechanism for passive insertion without energy supplement.  This is potentially 
due to the shapes of CNTs; that CNTs as elongated tubes are able to penetrate 
through the plasma membrane with lipid-membrane fusion, as a ‘nanosyringe’,23 
which is dependent on their hydrophobicity and stability (Figure 3.8) culture 
79 
 
media.24 This property of nanosyringe possibly hindered CNTs moving forward by 
free diffusion.  
 
Figure 3.5 Encocytotic internalization of CNT penetrants in 2D cell cultures.(a-d) 
Confocal microscopy images of HepG2 cells after incubation for 1 hour in serum-
free medium with 0.5mg/ml of CNTs-FITC (a,b) or CNTs-TGFβ1-FITC (c,d) at 
4°C (a,c) and at 37°C (b,d).  All scale bars are 10μm. (e) Quantification of CNTs-
FITC and CNTs-TGFβ1-FITC internalized by cells at 4°C and 37°C. The 
percentage in (e) refers to fluorescent area fraction of CNTs (green) to cells (red). 
a. 4 C  CNT-FITC b. 37 C CNT-FITC
c. 4 C CNT-TGFβ1-FITC






4°C CNT-FITC 4 C CNT-TGFβ1-
FITC
37°C CNT-FITC 37 C CNT-TGFβ1-
FITC




Figure 3.6 CNTs-FITC and their derivatives CNTs-TGFβ1-FITC entering cells at 
4 °C and 37 °C under conditions where active internalization processes are blocked 
in the presence of azide and 2-deoxyglucose. HepG2 cells were incubated for 20 
min in serum-free medium with CNTs-FITC (a) or CNTs-TGFβ1-FITC (b) at 4 °C 
and with CNTs-FITC (c) or CNTs-TGFβ1-FITC (d) at 37 °C. Area fraction of 
CNTs and their derivatives were calculated (e). Nuclei were stained with DAPI 
(blue) while the cytoplasm was stained with CellTracker™ CMRA (orange-red). 




Figure 3.7 Quantification of CNTs-FITC and their derivatives CNTs-TGFβ1-FITC 
entering cells by endocytosis at 4 °C and 37 °C. HepG2 cells were incubated for 20 
min in serum-free medium with CNTs-FITC (a) or CNTs-TGFβ1-FITC b) at 4 °C 
and with CNTs-FITC (c) or CNTs-TGFβ1-FITC (d) at 37 °C.  Nuclei were 
counterstained with DAPI (blue) and early endosomes are marked with early 





Figure 3.8 Stability of CNTs-FITC and CNTs-TGFβ1-FITC in EMEM without (a) 
and with (b) FBS of CNTs-FITC and CNTs-TGFβ1-FITC after 2 hours. 
 
  
3.4.2 Calculation of equilibrium constants 
Endocytosis term in R of Eq 3.3 for these permeants can be neglected in 
this tissue model and period of CNT diffusion experiment since endocytosis is 
arrested at 4°C.  Therefore, adsorption to, surface diffusion on, and desorption from 
the cellular membranes of CNTs have made the primary contributions to R.  The 
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where 𝑪𝒎𝒆𝒎 is the concentration on the cell membrane.  ka and kd are the first order 
rate constants for adsorption and desorption of CNT on membranes.25  𝛁′ is the 
Laplace operator for 2D diffusion and 𝑫𝒎𝒆𝒎 is the coefficient for the diffusion 
along the cell membrane. Since binding/unbinding processes are reversible and fast 
with characteristic times of milliseconds,25 we can add another equation to this 
system 
𝑪𝒎𝒆𝒎/𝑪𝒆𝒙 = 𝒌𝒂 𝒌𝒅⁄ = 𝑲                    Eq 3.7 
where K is the equilibrium constant (K > 0) for CNT two-phases distribution 
between the interstitial space and membrane surface. 
Note that  𝛁 and 𝛁′ have different systems of coordinates that are ‘natural’ 
for 3D bulk and 2D surface diffusion processes.  It is possible to transform 𝛁′ into 
Cartesian coordinates but it will require additional boundary conditions and 
separate geometrical description of the membrane surface.  Note also that 𝑫𝒎𝒆𝒎 is 
logarithmically dependent on the membrane curvature and the size of the 
permeant.13 Even after some simplification including Eq. 3.7, this system of 
differential equations is difficult for analytical solution.  It can be solved by 
numerically of using Monte Carlo (MC) simulations.   
Similar problem originated in the past for diffusion for small molecules in 
porous solids.17 Based on MC simulations of the diffusion pathways for combined 
2D (surface-confined) and 3D (bulk) diffusion, an apparent diffusion coefficient 
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can be calculated as Eq.3.1 based the assumption of association-dissociation 
equilibrium (Cbi /Cex = K)
15. 






                     Eq. 3.8 
where 𝑱𝒊 is the interstitial phase diffusive flux, 𝑱𝒎𝒆𝒎 is the cell membrane surface 
diffusive flux, 𝑫𝒆,𝒊  is the effective interstitial phase diffusivity, 𝑫𝒆,𝒎𝒆𝒎  is the 
effective cell membrane surface diffusivity (length2/time); 𝑪𝒆𝒙 is the extracellular 
concentration, 𝑪𝒃𝒊  is the cell membrane surface concentration. 𝒂𝒗  is volume 
ratio(cylinder layer-cell membrane to capillary-interstitial layer).  𝒓′ is the direction 
of net motion. 
For combined interstitial and cell membrane surface diffusion, an effective 
diffusivity can be described in terms of the diffusivities associated with an 
equivalent capillary and of tortuosity factors 𝞽 for the void and surface phases as 
Eq. 3.1. The parameters in the equation can be estimated using experimental results 
for hepatocytes, cellular spheroids, and tumors as following:  
𝒂𝒗 = 2π (interstitial space size) (cell membrane thickness)×L/π(interstitial space 
size)2×L 
 =2(cell membrane thickness)/(interstitial space diameter) = 2× 8nm/1343nm = 
0.012 26,27 













Da were shown in Table 1 of maintext 
𝟇 = 40%~80% (average: 60%) 28 









= 0.6  (assume heptocytes are spherical, d is the 
average radius) 
𝞽𝒆𝒙 = 𝞽𝒎𝒆𝒎 = 0.6, 𝟇 = 60%, and 𝒂𝒗 = 0.012.    
Dmem can be treated as a surface-averaged constant and was calculated for 




/s).13  Since lymph is 
essentially interstitial fluid, we should use diffusion coefficient of CNTs in lymph 
as Dex, i.e. (1.45±0.65)×10
-14 m2/s.9  Da from Eq 3.3 for CNTs-FITC and CNTs-
TGFβ1-FITC is equal to (0.9±0.3)×10-14  m2/s and (1.5±0.2) ×10-13 m2/s.  4 
Therefore, if consider the membrane diffusion as part of extracellular diffusion, we 
have 






 𝒂𝒗)  (K > 0)            Eq 3.9 





a. CNT-FITC:  
KCNT-FITC  = (0.9±0.3×10









/s /0.6 × 0.012) ≈0 (Range of 0~0.125) 
 
b. CNT-FITC-TGFβ1  
KCNT-FITC-TGFβ1 = (1.5±0.2×10









/s /0.6 × 0.012) ≈2.95 (Range of 1.81~5.06) 
Therefore, the equilibrium constants obtained from experimental data are KCNT-FITC 
= 0 and KCNT-FITCβ1-FITC = 2.95 for CNTs-FITC and CNTs-TGFβ1-FITC, 
respectively. These values are in agreement with each other as one would expect 
that affinity of surface ligands to the cells surface increases with addition of TGFβ1.  
The presence of carboxyl groups on CNTs-TGFβ1-FITC is likely to play a role as 
well because the latter are less adhesive to cells than the targeting ligand itself. 29  
Given the overall tendency for the CNTs-based permeants to adhere to cell 
membranes, the negative charges of CNTs-TGFβ1-FITC and CNTs-FITC (Table 
2.3) are likely to stimulate the lateral 2D diffusion be reducing internalization in 
the tissue model from HepG2 cells, which allowed unbounded CNTs to diffuse 
further and faster.   
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Thus, anomalously high values of Da of CNTs-TGFβ1-FITC should be 
attributed to the contribution of the lateral diffusion along the cellular surface to the 
overall transport.7, 9 Some electrostatic repulsion between CNTs-TGFβ1-FITC and 
cellular membrane facilitate the lateral motion. The partial confinement to the 
surface due to the presence of targeting ligands dramatically accelerate the transport 
of the permeant despite the overall increase in mass and results in anomalously high 
diffusivities. Similar transition from 3D to 2D diffusion in tissues is also known for 
some proteins that roll across the cellular membrane. 19,30 
3.4.3 Simulation model 
Simulations of CNT transport within dense tissue model require (i) 
appropriate methods to represent realistic model, cellular spheroid, and (ii) efficient 
algorithms to monitor nanotube trajectories within the interstitial void space and/or 
on the cell membrane surfaces that constrain these voids. Here, we describe these 
realistic, simulated structures and algorithm that we used for Monte Carlo 
simulation for diffusion; while we concurrently provide a rigorous comparison of 
the transport properties of CNTs in dense tissue.  
Given the equilibrium condition in the tissue environment, CNT transport 
is subject to Eq.3.1, where Di and Dmem are the inherent properties of nanotubes and 
homogeneous media in each phase according to practical experiments. 
Correspondingly, the variables K,  𝒂𝒗 and 𝟇 in the simulated tissue model are the 
uncertain factors from real cellular spheroids and difficult to measure in the 
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experimental setting. K is dependent on the affinity between CNTs and HepG2 cells, 
meanwhile, 𝒂𝒗 and 𝟇 are determined by the nature structure of cells and cellular 
spheroids such as thickness of cell membrane and diameter of interstitial space. 
Here we investigate how the change of these parameters affect the transport of 
nanotubes in dense tissue. 
First of all, in anomalous diffusion of CNTs incorporated with cell 
membrane surface displacement, equilibrium constant K is the key factor to affect 
CNT transport in dense tissue.  To demonstrate the method of data analysis and to 
provide a reference system, we first consider spherical obstructs, of which the 
surface has no binding (K=0) with CNT (Figure 3.9). Simulated apparent diffusion 
coefficient of this condition, (1.48±0.002) ×10-2 µm2/s, agrees with the value of 
interstitial diffusion rate, Di, as in free Brownian diffusion. In the simulation, travel 
distance (µm) associated time (min) (Figure 3.9a) and average value of apparent 
diffusion coefficient Da (Figure 3.9b) were simulated from 1,000 CNTs. Within 
the range of experimental K value within 1-10 in previous report4, the diffusion rate 
has significantly increased from (7.6±0.3) ×10-2 µm2/s to (12.9±0.5) ×10-2 µm2/s 
but not yet achieved the maximum.  When K increased up to 1000, apparent 
diffusion coefficients in cellular spheroid is converging to (13.6±0.4) ×10-2 µm/s2. 
The value had been inherently assumed to be the membrane diffusion coefficient. 
However, this convergence is ten folds smaller than membrane diffusion coefficient 
Dmem. The observed difference between simulated Da with large value of K and 
Dmem could be a consequence of inadequate steps of interstitial diffusion, which 
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result in no further movement of nanotubes with initial steps in interstitial space. 
This phenomenon indicated that balance between interstitial diffusion and cell 
membrane surface sliding against the curvature is essential for two-phase transport 
of CNTs. Moreover, the resulting apparent diffusion coefficients (1.1±0.03) ×10-1 
µm2/s at K = 2.95 from simulation show slightly lower than experimental data 
(1.5±0.2) ×10-1 µm2/s. It could be due to the discrepancy of structures between the 
theoretical model and the realistic tumor spheroid, especially, the void fraction and 




Figure 3.9 Chart of Simulated results with K =1-1000. Trajectories of CNTs 
associated time (a) and average value of apparent diffusion coefficient Da (b) were 




Now let us consider if the void fraction change can affect the simulation 
results. In the simulated model, we originally applied the value of average 
intercellular distance of 1.34 µm26. The void fraction 𝟇 is determined to be 56.4%. 
In addition, the simulated structures are also built with interstitial diameters of 0µm, 
1.93µm, 4.20µm and 7.78µm. The resulting structures accurately capture the 
morphology of the void space formed as 47.6%, 50%, 60%, 70% and 80% (Figure 
3.10a-c).31 The range of these fractions is reasonable within the surgical and 
radiological observation. The corresponding apparent diffusion coefficients were 
computed at the experimental equilibrium condition K=2.95 (Figure 3.10d).  
 
Figure 3.10 Fraction Volume (%) which is corresponding to interstitial space of 




The values of simulated Da increases with the 𝟇 decreases, and Da = 
(1.3±0.04) ×10-1 µm2/s with 𝟇 = 50% is approximate to the experimental value in 
cultured cellular spheroid. In another word, the experimental models, in fact, have 
lower void volume than real tumor tissue because they do not inculde blood vessle 
and lymth system. Therefore, the experimental value was higher than estimated, 
which was calculated according to both void fraction 𝟇 and volume ratio 𝒂𝒗 from 
reference images of tumor in vivo, average interstitial space size and cell membrane 
thickness. Overall, this trend establishes the fact that the structure of tissue/tissue 
model is essential for CNT transport, and the result also shows that the actual void 
fraction in practical cellular spheroids was lower than the estimated value in vivo. 
Although the construction of cells in tumor tissue and transport of nano-sized 
particles can be much more complex than the models in the ICC scaffold in vitro, 
these simulations provide a conceptual benchmark and prediction to compare 










The simulation results of CNT transport in cellular spheroids presented here 
make contact with previous work and to serve as a reference system. In the two-
phase diffusion model, apparent diffusion coefficient is depending on the void 
fraction of tissue structure and equilibrium constant K. We conclude that under the 
equilibrium state, the implications of higher affinity of nano-sized agent with cell 
membrane is essential and beneficial for its transport in dense tissue such as solid 
tumor. And the diffusion coefficient is, at the same time, associated with the void 
fraction (volume), of which the factor varies among individual patients or different 
types of cancer/diseases. In the future study, binding and lateral diffusion on lipid 
membrane of CNT or other nano-sized agents in dense tissue should be considered 











av surface-to-volume ratio 
Ci interstitial space concentration 
Cm membrane surface concentration 
Da equivalent diffusivity for calculation of void tortuosity 
Di interstitial space diffusivity 
Dmem membrane surface diffusivity 
K equilibrium constant 
MSD mean-square tracer displacement 
𝞽𝒊 void tortuosity 
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3D Cell Culture for NP Transport Study 
in Personalized Model: Hepatic Differentiation  
of Controlled-Size EBs in ICC Scaffolds 
 
4.1 Abstract  
Human stem cells such as embryonic stem cells (ESCs) and induced 
pluripotent stem cell (iPSC) hold promising potential as a renewable cell source for 
tissue regeneration and personalized drug screening. The stem cells in 3D culture 
systems for various ex-vivo application is advancing exponentially. ESC-derived 
specific cell lineages were strongly influenced by the size of embryoid bodies (EBs). 




fate for cardiogenesis and neurogenesis. However, desirable size for directed 
differentiation of ES cells to hepatocyte-like cells are still unknown. In this chapter, 
a 3D stem cell culture in inverted colloidal crystal (ICC) scaffolds with highly 
uniform porous structure was introduced. The size-controlled EBs can potentially 
apply to NP transport evaluation as personalized model. The sizes of EBs were 
controlled by varying diameters of pores in scaffold (90 µm, 170 µm, 200 µm, 270 
µm and 400 µm). Differentiation of ES cells into early hepatocytes was assessed 
by analyzing gene expression. We found that hepatic differentiation of ES cells 
were strongly regulated by the sizes of EBs and EBs equals to or larger than 180 
µm in diameter maintained the ability to differentiate to specific lineage and EBs 
in diameter of 202 µm induced highest yield of hepatic differentiation where the 
optimal pore size of scaffolds is 270 µm.   
4.2 Introduction 
Human stem cells such as embryonic stem (ES) cells and induced 
pluripotent stem cell (iPSC) are able to provide potentially unlimited resources of 
tissue for ex-vivo models for regenerated medicine and personalized drug screening 
especially for transport of nanomedicine in patient-specific tissue because this 




derived to a wide spectrum of cell types. For instance, ES cells can differentiate 
into neural cells, cardiomyocytes, hepatic and endothelial cells by forming 
embryoid bodies (EBs) and complement the variety of conventional animal models 
from human with more relevance and personalization. The size of EBs is a key 
factor in determining cell fate, and promoting differentiation toward 
cardiomyocytes3, chondrocytes4 or neural lineages5. A large amount of engineered 
microstructures have been used for study the effect on ES cell differentiating fate 
by regulating EBs size during development; and it has been further proved that the 
lineage specific differentiation from EBs for cardiac and neural fates are highly 
influenced by the size of EB. Recent study indicated cardiac differentiation of EBs 
in a wide range of sizes and geometries6, 100 μm ~500 μm in lateral dimensions 
and 120 μm in depth. It was concluded that the 300 μm micro-wells produced 
highest percentage of contracting EBs, and the smaller EBs are less likely to form 
contracting EBs, however, those contracting EBs formed a similar percentage of 
cardiomyocytes compared to larger EB sizes. An optimal size of EBs for 
chondrogenic differentiation were investigated by dividing pre-differentiated EBs 
into three groups, <100 μm, 100 μm ~150 μm and >150 μm 4; small EBs were more 
significantly to express the specialized chondrogentic markers. Cardiogenesis can 




cell differentiation was increased in smaller EBs in diameter of 150 μm 7. Yet, 
among all genesis of organs and tissues, liver is a key organ for cell therapies and 
drug discoveries. Thus, an effective and convenient liver tissue model generated 
from stem cells are always on demand.8–10,11 However, little is known regarding the 
size effect of EBs on generation of hepatocytes from ES cells.  
Several methods for size control of EBs, such as hanging drop (HD)12, 
multi-well plates13, laser direct-write14 and micro-patterned chips15,16–21, have been 
developed. HD method allowed individual cells spontaneously self-assemble but 
not all the formed EBs are spherical due to the cell spreading on 2D flat substrates. 
Various tools by micro-patterned methods provided external forces or confined 
geometry to control the diameters and homogeneity of EB formation, however, the 
formed EBs have still limited relatively high variance in diameters. In addition, 
most of these patterned tools are not able to satisfy both the engineering and tissue 
culture factors such as size control, mechanical properties, porosity and nutrient 
transportation at the same time.22–25 Moreover, cells must be pipetted manually into 
some of the devices, which is time-consuming and increases the likelihood of 
contamination during the process. Overall, these techniques have provided 
advances, but the goal of highly reproducible, efficient, scalable hepatic 




In this chapter, we utilized ICC scaffolds to form size-controlled EBs and 
to understand how size of EBs shall influence hepatic differentiation derived from 
ES cells. The ICC scaffolds have unique features with uniformly sized pores in the 
3D matrixes, which can afford a high yield production of controlled size spheroids 
in wide range, at the same time, it can provide efficient nutrient transport and cell-
cell interaction to enhance the quality and viability of cellular spheroids 22,26–28,29. 
The selected pore sizes of scaffolds were 90μm, 170μm, 210μm, 280μm, 400μm 
and HD method was used as a control method. The degrees of hepatic 
differentiation from ES cells into in each diameter was examined as well as the 
functions of obtained hepatocyte-like cells. This stem cell culture in 3D size-
controlled scaffolds also provides a promising tool for future study of NP transport 
in patient/disease-specific models. 
4.3 Materials and Methods 
4.3.1 Fabrication of ICC scaffolds in different sizes 
Dried 1 g of soda lime glass beads with average diameters of 90μm, 170μm, 
200μm, 270μm, 400μm (Thermo Fisher Scientific, MA) were dispersed in 5 ml of 
ethylene glycol. A glass shell vial (Fisher Scientific) connected with a long glass 




e) The complex unit was inserted in a glass tube (O.D. ¼10 mm, H ¼75 mm) that 
was halfway immersed in an ultra-sonic water bath (VWR), and the inner space of 
mold was filled with ethylene glycol. 20μl of glass bead suspension was released 
to the mold per 20 min until the thickness reached approximately 1 mm. After 
complete evaporation of ethylene glycol at 160 °C, the CCs were annealed for 4 h 
at 670–690 °C, depending on the size of beads, and then free standing CCs were 
extracted from the mold. 
Poly(acrylamide) hydrogel precursor solution (30% (w/w) acrylamide, 5% 
(w/w) bis-acrylamide, and 0.1% (v/v) N,N,N,N-tetramethylethylenediamine), 
prepared as described previously, was infiltrated into the CC by centrifugation and 
polymerized by addition of radical initiator (1% (w/w) potassium peroxideThe 
infiltrated CC was cut out from the hydrogel and immersed in 5% (v/v) hydrogen 
fluoride (HF) solution for 24 h to dissolve the glass beads. Later, ICC scaffolds 
were sequentially washed with pH 3.0 hydrochloric acid (HCl) solution, pH 7.2 
phosphate buffered saline (PBS) solution, and deionized water for 2 days in each 
solution with 3–4 times solution changing per day. ICC scaffolds were further 
freeze dried to completely remove remaining HF and reserved in dried state until 






Figure 4.1 ICC scaffold fabrication. SEM images of highly ordered colloidal 
crystals with different sized glass beads of 90 µm, 170 µm, 200 µm, 270 µm and 
400µm (a-e). Hydrogel precursor solution is later infiltrated into the colloidal 
crystals and polymerized. ICC scaffold geometry is created by dissolving beads 
from hydrogel matrix. The small spots on glass beads in (a-e) are contact points 
between beads, which later become channels in (f-j). Pore dimensions were reduced 
during the dehydration process for SEM sample preparation. 
 
4.3.2 ES Cell Culture 
129/Ola mouse embryonic stem (ES) cell line (ATCC, USA) was 
maintained at undifferentiated state in T-75 flasks (Fisher Scientific) on mitotically 
inactivated mouse embryonic fibroblast cells in Dulbecco’s modified eagle 
medium-high glucose (GIBCOBRL, USA) containing 15% fetal bovine serum 
(Hyclone, USA), 1× non-essential amino acids (Gibco BRL, USA), 2mM 




ESGRO® (LIF-ESGRO®), 100M 2-mercaptoethanol (Sigma, USA), 100U/ml 
penicillin and 100μg/ml streptomycin (Gibco-BRL). To form embryoid bodies 
(EB), 1,000,000 cells in a 25μl of dense cell suspension (4x106 cells/ml) was 
dropped on top of completely dehydrated hydrogel ICC scaffold using a micro-
pipette, and 975μl of media was gently added. Total culture volume was maintained 
at 1000μl, and half of media was changed every two days. As a control, ES cells 
were seeded by HP method (2000 cells per 25ul in each drop). All the medium was 
filtered using 0.22 μ SteriCup filter assembly (Millipore, USA) and stored at 4 °C 
for no longer than 2 weeks. 
 
 
4.3.3 Differentiation of ES cells to hepatocyte-like cells in vitro 
After 6 days of EB differentiation, cells in two culture systems were induced 
to differentiate towards hepatic direction by adding specific growth media. The 
composition of the optimized hepatocyte differentiation medium contained, 
DMEM (high glucose), 10% FBS, L-glutamine (1mM), non-essential amino acids 
(1%), L-mercaptoethanol (0.1mM), hepatocyte growth factor (HGF) 20μg/ml, 




1X), dexamethasone (10-5mM). 30–32 (Figure 4.2) 
 
Figure 4.2 Hepatic Differentiation of EBs in ICC scaffolds. 
 
4.3.4 Live/Dead Assay Analysis 
Cell viability was observed using a Live/Dead Viability Kit (Invitrogen). 20μl 
of 2mM EthD-1 stock solution was added to 10mL of sterile, tissue culture–grade 
PBS solution (PH=7.4) and then to give an approximately 4μM EthD-1 solution. 
The reagents were combined by transferring 5μl of 4mM calcein AM stock solution 




4μM EthD-1 working solution is then added directly to cell culture. The stained 
cells were visualized under fluorescence microscope (Zeiss Axiovert 100M 
inverted microscope) at 20×. Digital images were acquired with a charge-coupled 
device (CCD) camera and analyzed by an imaging system (LSM, Zeiss). 
 
Figure 4.3 Confocal images (a–f) of live/dead stained EBs formed in ICC hydrogel 
scaffolds on Day 6. Green indicates live cells and red indicates dead cells. EBs 
obtained by hanging drop as a control (a). EBs induced by ICC scaffolds with 
diameters of 90 µm, 170 µm, 200 µm, 270 µm and 400µm (b-f). Most cells showed 






4.3.5 Detection of EBs formation and hepatic specific proteins by confocal 
microscope  
Cultured ES cells grown in scaffolds, after 6 days and 20 days of 
differentiation were fixed with 4% freshly prepared paraformaldehyde for 20min at 
room temperature. For specific protein detection such as nuclear proteins, the cells 
were permeablized with 0.3% Triton X-100 (Sigma, USA) for 5min at room 
temperature and processed further. After aspirating the fixative, cells were washed 
three times for 5min each with PBS. Non-specific binding was blocked with PBS 
containing 1% rabbit serum in PBS for 2h at room temperature. The cells were then 
incubated with primary antibody (Oct-3/4, SSEA-1, GATA-4; Santa Cruz, USA, 
CK-18; Chemicon, USA; 1:100) in 10% rabbit serum overnight at 4 °C. Next, the 
cells were washed with 1× PBS three times for 5 min each. The cells were then 
incubated with secondary antibodies anti-rabbit-FITC for SSEA-1 and CK-18; anti-
rabbit-TEXAS RED for Oct-3/4 and GATA-4 (Santa Cruz, USA; 1:500) in 0.1% 
rabbit serum at 37 °C for 30min. After giving three washes (5min each) with PBS, 
the cells were exposed to 1mg/ml DAPI solution for 1min. After washing the cells 
twice for 5min each with 1X PBS, they were ready for confocal imaging. Images 





4.3.6 Detection of stored glycogen by periodic acid schiff (PAS) staining 
The PAS technique was used to determine the presence of insoluble stored 
glycogen content in the cells. Briefly, hepatocyte-like cells after 20-day 
differentiating in scaffolds of different pore sizes were fixed with 4% 
paraformaldehyde at room temperature for 15min. It was then oxidized with 1% 
periodic acid for 5min, rinsed with distilled water for 5min and treated with Schiff’s 
reagent for 10–15min. After rinsing in distilled water for 5min, scaffolds were 
counter stained with Mayer’s hematoxylin stain for 30 s and observed under light 
microscope. 
 
4.4 Results and Discussion 
4.4.1 ES cells and EBs cultured in ICC scaffolds 
Polyacrylamide hydrogel ICC scaffolds were prepared by utilizing colloidal 
crystals (CC) as templates (Figure 4.1a-e). To control the pore sizes of scaffolds, 
we use glass beads with five diameters: 90μm, 170μm, 200μm, 270μm and 400μm 




with high connection was achieved, which in turn was transferred into ICC 
geometry high porosity as previous method27 (Figure 4.1f-j). To culture ES cells 
within porous 3D structures, the cells were seeded into scaffolds, allowing the cells 
to settle within the caves. One major feature of ICC scaffolds is that the resulting 
size and shape of EBs are similar to the 3D structure in which they are grown. In 
addition, EBs in scaffolds can contact with each other due to the highly porous 
connection, in contrast to previously reported concave micro-well or micro-
patented chips.6, 7, 15, 18, 19  
ES cells cultured within ICC scaffolds were physically constrained and 
formed EBs that were homogeneous in size. The viability of EBs was checked by 
standard live/dead cell viability assays which consisted of calcein AM and ethidium 
homodimer (EthD-1) addressing plasma membrane integrity and esterase activity, 
respectively (Figure 4.3). Stained with live/dead assay, live cells are green, while 
dead cells show red. The results demonstrated that cells cultured for 6 days 
remained viable regardless of the difference in diameters. The biocompatibility of 
ICC scaffolds allows further differentiation of culturing ES cells in vitro. EBs were 
harvested after culturing for 5 days within ICC scaffolds with pores in five 
diameters. The cells were stained as green (5-chloromethylfluorescein diacetate) 





Figure 4.4 Confocal images with bright field of EBs formed in ICC hydrogel 
scaffolds on Day 3. ES cells are cultured on Petridish as control (a). EBs are grown 
in ICC scaffolds with pore diameters of 90µm, 170µm, 200µm, 270µm and 400µm 
(b-f). Cells were stained with CMFDA (5-chloromethylfluorescein diacetate) as 
green color. 
 
4.4.2 Diameter distribution of size-controlled EBs in ICC scaffolds 
To study how the pore sizes of ICC scaffolds control EBs formation in 
diameter with desirable precision, the scaffolds with five different diameters (90μm, 
170μm, 200μm, 270μm and 400μm) were prepared, and seeded with the same 
initial number of ES cells. EBs were retrieved after culturing for 6 days from ICC 




formed and exhibited relatively homogeneous sizes (Figure 4.4b–f) directly related 
to the initial pore sizes of ICC scaffolds in contrast to the more heterogeneous size 
distribution of EBs formed by HD method (Figure 4.4a). The dependence of 
spheroid diameter and uniformity of their size on the ICC pore size was quantified 
using image analysis. As a control, HD method was also used for formation of EBs. 
The distribution of EB sizes by HD and in ICC scaffolds were shown in Figure 4.5 
with a fine level of control (P <0.0005) over the diameter. 
The average sizes of EBs on day 6 of culture in scaffolds with different 
diameters and by HD method were 68 µm, 152 µm, 180 µm, 202 µm, 253 µm, 402 
µm (Figure 4.5a), which were well fit to a Gaussian distribution. The size 
distribution of EBs was shown in Figure 4.5b. The porous structure with 
controllable size of ICC scaffolds constrained led ES cells forming predictable, 
uniform-sized EBs, particularly for the smaller sized pores, in contrast to more 
heterogeneous EB sizes resulting from unconstrained, conventional culture in 
larger sized pores of ICC scaffolds, and especially from HD method. When the size 
of pores becomes larger than 270 µm, other factors such as nutrient delivery to the 
interior cells of EBs would be a more critical issue than physical restriction, and 






Figure 4.5 EBs size control corresponding to pore dimensions of ICC. ES cells 
were seeded in each ICC scaffolds having 90, 170, 200, 270 and 400 µm pore 
dimensions to get the average diameters of EB size after 6 days culturing. (a)  
Each group has significantly different sizes of EBs. Five scaffolds were used in 




4.3.3 Effect of EB size on hepatic differentiation 
Once predictable EBs size distributions had been obtained from size-
controlled ICC scaffolds after 6 days, ES cells were differentiated into hepatic fate 
for another two weeks following the existing protocol and the differentiation media 
was made referred to previous publications3,29,30. The effect of EB sizes on hepatic 




First stage of differentiation. Differentiation of EBs in ICC scaffolds at the 
first stage was checked on day 3 (Figure 4.6) and day 6 (Figure 4.7) by 
immunocytochemical staining against pluripotency markers, Oct-3/4 and SSEA-1. 
Oct-3/4 is a master regulator of pluripotency and has been shown to be critical for 
maintaining ES cell character,30-32 and it also governs three distinct fates of ES cells 
for the initial formation of a pluripotent founder cell population in the mammalian 
embryo. A less than two-fold increase in expression causes differentiation into 
primitive endoderm and mesoderm, which includes the early stage of hepatic fate.33  
SSEA-1 is a marker expressed on murine embryonal carcinoma cells, ES cells, and 
primordial germ cells. Murine SSEA-1 expression decreases with progress of 
differentiation in the early stage.31, 34, 35  In the EBs immune-labeled on day 3 and 
day 6 of culture, Figure 4.6 and Figure 4.7 compared representative those EBs 
from 90 µm to 400 µm. From the image of EBs, similar ratios of SSEA-1 expression 
on individual cell surface in EBs were detected in ICC scaffolds with all the pore 
sizes except 90µm, which was in agreement with the expression of Oct-3/4. 
Smallest EBs have limited expression of SSEA-1 and OCT3/4, which means ES 






Figure 4.6 Confocal microscopy images differentiated EBs on day 3. EBs were 
stained for markers of differentiation at first stage. SSEA-1 (a-e) is shown in green, 
and OCT-3/4 (f-j) is shown in red, while the cell nuclei, counterstained with DAPI, 
are in blue. Each image is z-stack from top to bottom of an EB in scaffolds with 
different pore size.  
  
 
Figure 4.7 Confocal microscopy images differentiated EBs on day 6. EBs were 






Quantitative study of the change for gene expressions from day 3 to day 6 
were shown in Figure 4.8. SSEA-1 decreased more significantly in the groups with 
larger size of 270 µm and 400 µm while no obvious change was observed in other 
groups. This agreed with the previous results that larger EBs tend to differentiate 
into primitive germ layers.18 
 
Figure 4.8 First stage of differentiation. Endoderm and Mesoderm development 
were indicated by OCT3/4 level change. Decrease of SSEA-1 expression indicated 
the progress of differentiation process. 
 
In another aspect, Oct-3/4 expression of most groups increased slightly with the 
sizes of EBs except the one with a diameter of 200 µm. The peak of increase appear 




mesoderm differentiation;33,34 while the expression of OCT-3/4 in other groups was 
within 0.5~1.5 fold, which indicated the ES cells still maintained pluripotency no 
matter the expression increase or decrease. Overall, according to the evaluation of 
early differentiation, larger EBs have better functionality for further induction of 
specific lineage and the size of 270 µm shows the highest the potential for hepatic 
fate developed from endoderm.  
Analysis of hepatic differentiation by immunofluorescence. After culturing 
for 6 days in regular medium, EBs within ICC scaffolds were transferred to a new 
48-well plate and cultured in hepatic differentiation medium for additional 14 days, 
resulting in hepatic differentiation. Hepatic differentiation of EBs cultured in ICC 
scaffolds with different pore sizes was analyzed by evaluating the expression of 
gene markers. The EBs were fixed and immune-stained with GATA-4, CK-18, and 
counterstained with DAPI. GATA-4, an early transcription factor, which indicates 
onset of hepatic maturation, was highly expressed in the differentiating cell 
population.35–37 Meanwhile CK-18 is a mature hepatocyte marker38,39. The 
percentage of differentiated EBs into hepatocyte-like cells was high (Figure 4.9 b-
e, g-j). However, the smallest EBs (Figure 4.9 a, f) demonstrates no differentiating 






Figure 4.9 Confocal microscopy images differentiated EBs in ICC scaffolds with 
diameters of 90µm, 170µm, 200µm, 270µm and 400µm on day 21. EBs were 
stained for markers of hepatic differentiation. GATA-4 (a-e) is shown in red, and 
CK-18 (f-j) is shown in green, while the cell nuclei, counterstained with DAPI, are 
shown in blue. Images represent scans near the center of the EBs. 
 
 





Here we found the cells in scaffolds with the pore sizes more than 90 µm 
expressed proteins of resultant GATA-4 and CK-18, which is indicative of 
hepatocyte-like cells to a certain extent. Accordingly, the gene expression in 
differentiated cells was significantly reduced when the diameter of pore size was 
90 µm, although they have showed decrease of SSEA-1 at the first stage of 
differentiation, which indicated ES cells could not form functional EBs within the 
hole in a small diameter and differentiated into specific lineages. GATA-4 and CK-
18 are apparently observed in scaffolds with pores of 270 µm, while the expressions 
are lower in the pore of 170 µm, 200 µm and 400 µm. Processed imaging data 
Figure 4.10, which shows the area fraction of marker-positive cells to DAPI-
positive cells, verified the fact that in the scaffolds with pore size of 270 µm, cells 
showed highest expression for both markers of hepatic differentiation as 38±2% of 
GATA-4 and 46±3% of CK-18. In contrast, in the scaffold with the pore size of 90 
µm, no mature hepatocyte markers CK-18 was detected. The highest production of 
hepatocyte-like cells in scaffolds with pores of 270 µm was in agreement with the 
endoderm development in the early stage of differentiation. The yield of 
hepatocyte-like cells derived from EBs are highly affected by not only the directed 
differentiation stage but also the early development of three germ layers. From the 




201.7±29.6 µm cultured in the scaffolds with pore size of 270 µm among all the 
groups.  
Functionality test by PAS. To provide additional assessment of hepatic 
differentiation from EBs derived from ICC scaffolds with pores in five different 
diameters, PAS staining were used to detect the glycogen level that the hepatic-like 
cells stored. PAS is one of the metallic functions of hepatocytes.40,41 To observe 
cells in an entire EB, we sectioned the EBs together with ICC scaffolds into 
histology slices with thickness of 1µm/slice after 21 day culturing. Middle plane of 
the sectioned slices were examined under optical microscope for each group. 
PAS staining revealed cytoplasmic deposits of glycogen stained with 
purple-magenta color in hepatocyte-like cells. The stained cross-sections of ICC 
scaffolds are shown in Figure 4.11, where stained hepatocytes (HepG2, ATCC) 
were used as a control which did show positive staining (Figure 4.110a). From the 
result of PAS staining, we found limited glycogen stored in 90 µm EBs (Figure 
4.11b) while larger size EBs shows the functionality of glycogen storage (Figure 
4.11c-f). In the control group of hepatocytes exhibited the ratio of PAS staining-
positive cells (98%±2%) to overall number of cells, the cytoplasmic glycogen 




the stain was distributed uniformly throughout the EBs in group of scaffolds with 
pore size which is more than 200 µm, while the glycogen was detected only a thin 
layer close to the surface of EBs in diameter of 152.0±21.5 µm.  
 
Figure 4.11 PAS staining of EBs in ICC hydrogel scaffolds on Day 21. Stained 
hepatocytes are as control (a). EBs (b-f) are obtained by ICC scaffolds with 
diameters of 90,170,200,270 and 400µm. Images are the cross-sections of scaffolds, 
which means the stained cells are from middle-plane of EBs.  
 
In this case, the glycogen is possibly stored in myocyte-like cells which are 
from ectoderm of an embryo during the differentiation.42,43 In contrast, glycogen 




400um which had large amount (>80%) of hepatic glycogen-stained cells (Figure 
4.12). These accumulations of PAS-positive material are seen as pink areas 
throughout the EBs. This result was also consistent with the expressions of early 
stage markers of differentiation for endoderm layer and hepatic specialized markers. 
From these results, we concluded that the optimal diameter of circular domains for 











This work demonstrated that ICC scaffolds with controllable size of pores 
was able to form uniform EBs within a narrow size distribution. Derivation of EBs 
from scaffolds with interconnected pores facilitating cell-cell communication. 
These functional EBs could be differentiated into hepatocyte-like cells in certain 
degrees. Expression of hepatic differentiation markers and liver-specific function 
were demonstrated to be strongly dependent on the diameter of EBs. We anticipate 
the presented system will contribute to the development of various physiological 
and pathophysiological 3D tissue models which can be served as a valuable tool for 
understanding in vitro differentiation from ES cells for personalized cell therapy 
and drug screening. In addition. these result support the 3D cell culture platform 
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Preliminary study for 3D Stem Cell Culture:  
Layer-by-Layer Surface Modification for  
Bone Marrow Stromal Cells Culture in ICC Scaffold 
 
5.1 Abstract 
The bone marrow microenvironment containing bone marrow stromal cells 
(BMSCs) and complex set of chemical and physical cues provides the structural 
and physiological support for hematopoietic stem cells (HSCs). Better 
understanding and appropriate tools to control BMSCs signaling are important in 
emulating HSC niches ex-vivo. However, there are difficulties associated with drug 
discovery for immunotherapy and bone tissue engineering to which BMSCs are 
essential. Although BMSCs have the potential to replicate as undifferentiated cells 
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or differentiate to lineages of mesenchymal tissues, including bone, cartilage, fat, 
tendon, muscle, and marrow stroma, the fate of BMSCs within bone marrow niche 
in three-dimensional (3D) matrices in vitro or in vivo are still unknown. In this 
chapter, we discuss the BMSCs grown in 3D Inverted Colloidal Crystal scaffolds, 
layer-by-layer 3D surface modification is utilized and allow controllable cues in 3D 
porous structures. The results show clay/PDDA modified surface in 3D matrice 
promote BMSC differentiated to Chondrogenic lineages which indirectly 
influenced from the bone mimetic coating.  
 
5.2 Introduction 
The bone marrow microenvironment containing bone marrow stromal cells 
(BMSCs)1 and complex set of chemical and physical cues 1–3 provides the structural 
and physiological support for hematopoietic stem cells (HSCs) by presenting 
membrane-bound ligands, secreting chemokines and potentially other intercellular 
signaling processes 4. A large amount of studies have proved the necessity of 
BMSCs for the maintenance of HSCs in long-term culture in vitro5–7 that are 
increasingly applied to regenerative medicine, immune therapies and personalized 
immune response of new drugs.8–10 Therefore, comprehensive understanding and 
appropriate methods of control of BMSCs signaling are important in emulating 
HSC niches ex-vivo.1,2,8  
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BMSCs have the potential to replicate as undifferentiated cells or 
differentiate to lineages of mesenchymal tissues, including bone, cartilage, fat, 
tendon, muscle, and marrow stroma.11–13  Like many stem cells, BMSCs may 
differentiate into distinct lineages depending on which cues are present in the cell 
culture environment14,15 such as growth factors,16 cell adhesion,17 cell shape,18 
mechanical forces,19 and substrate rigidity20,21. However, although differentiation 
fate for hematopoietic stem cells and other stem cells is partially known8,22,23, the 
fate of BMSCs co-cultured with them as well as the factors that control the 
phenotype and morphology are still puzzling. Three dimensional (3D) cultures in 
engineered scaffolds have been used as a tool to study cell-cell and cell-matrix 
interactions for recent decade, for instance, to investigate the role of specific cues 
in affecting HSC fate 9,18,20,21,24–26.  The controllable surface properties and existing 
data on HSCs in 3D matrices enable the 3D engineered scaffold a promising tool 
to understand BMSC in bone marrow microenvironment. Surface properties of 
these scaffolds were often modulated through the attachment of specific functional 
groups or proteins with necessary biological functions to regulate cellular behavior, 
however, fewer techniques can be applicable to existing 3D substrates other than 
two dimensional (2D) biological surface modification methods because of limited 
diffusivity within the porous internal structures. In addition, physical properties of 
the scaffolds such as stiffness of the scaffolds are generally modified by changing 
the composites of materials. Layer-by-layer (LBL) surface coating is a promising 
technique to modify 3D matrix surface properties with various materials and this 
134 
 
method is able to obtain different physical properties without re-fabricating the 
scaffolds.27–29  
In this chapter, Inverted colloidal crystal (ICC) scaffolds with LBL bone 
mimetic surface modification are used to study the behavior of BMSCs in 3D 
culture ex-vivo. 3D cell culture scaffolds with porous structures can be coated using 
the LBL technique as long as there is no serious mass transport limitation.30,31 To 
provide adequate adhesion of stromal cells, the pore surface of ICC hydrogel 
scaffolds was coated with clay and Polydiallyldimethylammonium chloride (PDDA) 
multilayer following the LBL technology32. PDDA is a positively charged polymer, 
while clay is negatively charged nano-sized particles. The thin layer of nano-
composite prepared on the surface of the scaffold is mechanically compatible with 
the hydrogel; the clay layer create a bone-mimetic coated surface of 3D scaffolds 
with its nanoscale roughness, increased charging on the surface, and created much 
stiffer film than original composites as hydrogel. 30,31,33,34 
5.3 Materials and Methods 
5.3.1 LBL surface modification on ICC scaffolds 
Fabrication technology of the primary ICC hydrogel scaffold was described 
in Chapter 2 and Chapter 4. Polystyrene (PS) beads with diameter of 120um were 
used instead of glass beads.34 The surfaces of scaffolds were coated with the 
sequential deposition of positively charged 0.5 wt% 
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Polydiallyldimethylammonium chloride (PDDA, Sigma, MW= 200 000) solution 
for 30 min, and a negatively charged 0.5 wt% clay nanoparticles with average 1 nm 
thick and 70–150 nm in diameter (Southern Clay Products) dispersion for 30 min. 
(Scheme 5.1) Each adsorption step was followed by rinsing in deionized water for 
30 min, and all processes were performed under a gentle flow generated by a stirrer 
in a beaker. Cyclic repetition of the polymer adsorption, rinsing, clay adsorption 
and rinsing process was carried out 3, 5 and 7 times and all process ended with clay 
layer. 
5.3.2 Bone marrow stromal cell culture 
Human bone marrow stromal cells HS-5 (CRL-11882, ATCC) were 
cultured with DMEM with 4mM L-glutamine, 4.5g/L glucose, 1.5g/L sodium 
bicarbonate, 10%(v/v) fetal bovine serum (FBS),  and 1%(v/v) penicillin-
streptomycin. Firstly, cells are maintained in T-75 culture flasks (Bottom area: 
75cm2). Once cell growth reached approximately 80% confluence, they were 
detached from the culture flask using 0.25% (v/v) trypsin–EDTA solution and 105 
cells were seeded on top of UV-sterilized scaffolds which were then placed in a 96-
well plate. Culture volume was maintained 250 μL and media was changed every 
other day. In order to characterize stromal cell growth in 3D scaffolds, HS-5 cells 
were stained with 5μM cell tracker green CMFDA dye in some cases. HS-5 cells 
are cultured in scaffolds for 5 days. The cells growing within the LBL-modified 
scaffolds were imaged under an Zeiss confocal microscope with 10× or 20× 
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objective. A 488 nm laser was used for excitation and emission signals were 
collected within 515–550nm window. Transmission image was overlaid with 
fluorescent image to confirm the location of cells within pores. 
 
Scheme 5.1 Schematic of clay/PDDA LBL surface coating of ICC hydrogel 
scaffold. (a) Schematic of PDDA and Clay nanoparticles. (b) Schematic of LBL 
surface coating procedure. 
 
5.3.3 Viability of BMSCs in scaffolds   
Standard live/dead cell viability assays, were used to observe viability of 
BMSCs in ICC scaffolds with or without LBL modification. The assay consisted 
of calcein AM and ethidium homodimer (EthD-1) addressing plasma membrane 
integrity and esterase activity.  The result indicated that the BMSCs proliferate 
normally in contact with surface of scaffolds.  Cell viability was verified by 





5.3.4 Immunostaining of bone marrow stromal cells in three potential lineages 
Cultured HS-5 cells grown in scaffolds after 7 days and 21 days were fixed 
with 4% freshly prepared paraformaldehyde for 20min at room temperature. For 
specific protein detection such as nuclear proteins, the cells were permeated with 
0.3% Triton X-100 (Sigma, USA) for 5min at room temperature followed by 
aspirating the fixative. Cells were washed three times for 5min each with PBS after 
membrane permeation. Non-specific binding was blocked with PBS containing 1% 
rabbit serum in PBS for 2h at room temperature.  
The cells cultured for 7 days were then incubated with primary antibodies 
((Santa Cruz, USA): the chondrocyte-specific marker Sox-9 and collagen type II 
(COL2A) 35,36, and osteocyte-specific marker, alkaline phosphatase (ALP) and 
runt-related transcription factor 2 (RUNX2)  in 10% rabbit or mouse serum 
overnight at 4 °C 37–39. Next, the cells were washed with PBS three times for 5 min 
each. The cells were then incubated with secondary antibodies anti-rabbit-FITC for 
(Santa Cruz, USA; 1:500) in 0.1% rabbit or mouse serum at 37 °C for 30min. After 
giving three washes (5min) with PBS, the cells were exposed to 1mg/ml DAPI (4', 
6-diamidino-2-phenylindole) solution for 1min. As a result, the nucleus of cells are 
stained as blue. After washing the cells twice for 5min each with 1× PBS, they were 
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ready for confocal imaging. Images were analyzed by ImageJ software 
(http://rsbweb.nih.gov/ij/). Following 21 days culture period, adipogenic markers 
peroxisome proliferator-activated receptor (PPARγ2) and acyl-CoA synthetase 
(ACSL5) were examined by the same method above40,41. 
 
5.3.5 SEM of bone marrow stromal cells grown in ICC scaffolds 
To investigate the attachment, spreading and differentiated morphologies of 
BMSC layer on scaffolds, the time points 3, 9, and 14 days were selected. After 3, 
9, and 14 days of culturing, samples were prepared for scanning electron 
microscopy as follows. Firstly, the medium on these samples was replaced with 2.5% 
glutaraldehyde in EMEM without serum and fixed for 30 min at room temperature. 
Then they were washed by PBS (pH 7.2) for three times (15min). The samples were 
dehydrated through a graded series of ethanol from 50, 60, 70, 80, 95, and 100%. 
The specimens were mounted on aluminum holders and sputter-coated with 
conducting layer of gold platinum for 90 seconds. The samples were examined by 







5.4 Results and Discussion 
Surface properties of the scaffolds that determine cell adhesion and other 
substrate-cell interactions represent some of these factors.   In this work, we studied 
the behaviors of BMSCs in regard to the changes of substrate properties in an 
artificial bone marrow matrix in vitro based on a 3D scaffold with inverted colloidal 
crystal (ICC) geometry.  Highly uniform pores in ICC scaffolds with a diameter of 
120 µm mimic the geometry of actual bone marrow matrix34 (Figure 5.1a).  
Besides that the structure of ICC scaffolds offer other benefits for bone tissue 
engineering such as a high degree of structural control, complete interconnectivity 
of cavities, and mechanical robustness.34 To understand the effect of cell adhesion 
and substrate property changes on BMSC supportive layer, scaffolds were coated 
with layers of transparent bone –mimetic nanocomposite.  It was created on the 
surface of ICC scaffolds by LBL assembly from clay nanoplatelets and 
polydiallyldimethylammonium bromide (PDDA).27,28 The LBL coating was started 
with a PDDA layer and finished with a clay layer as to support stromal cell 
adhesion.42   Seven bi-layers of clay/PDDA nanocomposite in ICC surface was 
visualized by confocal microscopy using FITC as fluorescent label that was added 
to PDDA during the deposition.  The feasibility of 3D LBL coating was confirmed 
by green fluorescence nicely formed 3D clay/PDDA LBL film was observed under 





Figure 5.1 ICCs were prepared with PS beads as template (D=120μm). (a)  All 
pores are open to the outer fluid which facilitates cell motility and media exchange 
in a dynamic culture condition. Seven bilayers of fluorescent labeled PDDA (green) and 
clay NPs on ICC hydrogel scaffold soaked in phosphate buffered saline (b). 
 
Human bone marrow stromal cell line, HS-5, were used to investigate 
cellular responses of the support stromal cells to surface properties of bone marrow 
scaffold in vitro, This cell line was stabilized and generally used as support cells 
for hematopoietic stem cells7,43, which can provide growth factors and signaling 
communication to stem cells to mimic the bone marrow stromal tissue function. 
Established bone marrow stromal cell line HS-5 were seeded in the scaffolds and 
maintained in specific culture media. Live/Dead Viability/Cytotoxicity kit (Life 
Technologies), which consisted of calcein AM and ethidium homodimer (EthD-1) 
addressing plasma membrane integrity and esterase activity, was used to monitor 
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the growth and viability of BMSCs in the scaffolds on day 3, 9 and 14 under the 
confocal microscope. In the confocal images, green cells are alive, while cells 
stained red are dead. Cells in the scaffold with and without LBL coating both 
appeared in green while there was no cell stained in red. The result indicated the 
cells maintained good viabilities in both types of scaffolds (Figure 5.2). In addition, 
the confocal images also show the cells have better adhesion on the LBL coated 
ICC scaffolds and most of the cells formed thick plaques on the pore surface. In 
contrast, the cells in control scaffolds without LBL coating tend to aggregate in the 
center of the pores and formed small spherical clusters.  
 
Figure 5.2 HS-5 cells were cultured on non-coated ICC hydrogel scaffolds as 
control (a-c) and scaffolds with 7 bi-layers of PDDA-Clay (d-f). Confocal images 
were taken on day 3, 9 and 14 where cells were stained with Live/Dead 
Viability/Cytotoxicity kit. Cell density at seeding is 80,000 cells/scaffold for all the 
groups. Scale bar: 200µm. 
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This trend became obvious after 9 days of culturing (Figure 5.2e, f). Coated clay 
particles created nanoscale roughness, increased charging on the surface, and 
created much stiffer film than hydrogel32,34. Increase of Young modulus of the 
scaffolds (Figure 5.3) was also a primary factor improving the adhesion of cells to 
materials 44. Therefore, the changing of cell aggregation with LBL coating is due 
to clay surface which enhanced BMSCs adhesion on the substrate, thereby change 
the shape and morphology of cells.  
 
 
Figure 5.3 Young Modulus. The compressive modulus of ICC scaffolds with 3, 5, 
7 bi-layers of clay/PDDA modification. The compressive modulus was within the 





The cells were extracted from the scaffolds right after imaging on day 3, 9 
and 14 and the density of cells were evaluated in all groups of scaffolds. As a result, 
without LBL the cells proliferated faster and achieved 1340,000 ±50,000 
cells/scaffold comparing to 725,000±25,000 cells/scaffold in the LBL group from 
the original density (Figure 5.4). Two potential factors can be considered to result 
in difference of cell proliferation. One is that the better adhesion of cells on the 
LBL-modified surface in scaffold prevented the agitating off the cells from the 
substrates in the same experimental condition. The other is that BMSCs in LBL-
modified scaffolds spontaneously differentiated and transformed to specific 
lineages of cells, hence the reduction of self-renewal cells and increase of 
differentiated cells were observed in the 3D culture 45–47. The LBL-modified 
scaffolds were examined under optical microscope after trypsin treatment and 
extraction of cells, however, only few cells still attached on the surface which 
exclude the former potential cause. Although the phenotypic and functional 
properties of HS-5 cell line have been characterized 7,43, the fundamental question 
of how or whether self-renewal is regulated remains unclear. In most cases, HS-5 
cells as supporting cells shall maintain potent proliferation with HSCs culturing, 
however, the differentiation of BMSCs cannot be prevented in long-term cultures48. 
Thereby, the potential differentiation of HS-5 cells may be the primary cause of 
density difference between control ICC scaffolds without LBL and LBL-modified 
ICC scaffolds, as well as the morphology change toward plaque-shaped BMSCs 




Figure 5.4 HS-5 cells were cultured on ICC hydrogel scaffolds as control (non-
LBL) and scaffolds with 7 bi-layers of PDDA-Clay. Cells per scaffold were counted 
on day 3, 9 and 14 under microscope on hemocytometer.  
 
To verify the morphology change of BMSCs clusters in LBL scaffolds, 
SEM images were taken after culturing for 9 days. In control ICC scaffold the cells 
did not strongly adhere to the surface and have been washed away during the 
sample preparation, even without trypsin treatment (Figure 5.5a, b), meanwhile, 
dense plaques of cells were observed in LBL-modified scaffold (Figure 5.5c, d). 
Noticeably, the scaffolds with LBL still maintained the shape of uniform porous 
structure comparing to the deformed structure in control scaffold during the 
dehydration process since LBL coating enhance the stiffness of the 3D matrix.12 
Furthermore, nano-sized porous structure was observed on the surface of the 
BMSCs plaque (Figure 5.5b). This feature shared the similarity of the physical 
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appearance with cartilage tissue with porous and permeable extracellular 
environment consisting of chondrocytes in vivo.49  
 
Figure 5.5 SEM images of of HS-5 cells on control scaffolds without coating (a 




As stated previously, BMSCs have the potential to differentiate into 
multiple lineages of cells in bone tissue such as adipocytes, chondrocytes and 
osteocytes aroused from the supporting complex structure.13 LBL bone-mimetic 
modification on surface of scaffolds stimulated BMSCs forming bone-specific cells. 
To understand how LBL coating on the supporting scaffold influence cell 
phenotype change, protein markers of three lineages were studied by 
immunofluorescence staining. The chondrocyte-specific marker, Sox-9 and 
COL2A 35,36 (Figure 5.6), and osteocyte-specific marker, ALP and RUNX2, 37–39  
were examined on day 7 of cell culture (Figure 5.7). Afterward, following 21 days 
culture period, adipogenic markers peroxisome proliferator-activated receptor 
(PPARγ2) and acyl-CoA synthetase (ACSL5) were observed at the end of the 
culture40,41 and show very limited expressions (Figure 5.8).  
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Figure 5.6 Immunofluorescence staining of lineage-specific markers of HS-5 Cells 
on LBL ICC scaffold with 7 bi-layers of PDDA/Clay coating: markers of 




Figure 5.7 Immunofluorescence staining of lineage-specific markers of HS-5 Cells 
on LBL ICC scaffold with 7 bi-layers of PDDA/Clay coating: markers of osteocytes 





Figure 5.8 Immunofluorescence staining of lineage-specific markers of HS-5 Cells 
on LBL ICC scaffold with 7 bi-layers of PDDA/Clay coating markers of adipocytes 







The quantitative analysis by image processing (Method) based on confocal 
images with immunofluorescence staining (Figure 5.9).  As a control in 2D culture 
before seeding in the ICC scaffolds, the expression of all markers for three lineages 
on day 7 and day 21 are significantly lower than in 3D matrix with LBL 
modification, which confirmed the gene expressions have changed with the 
transition of cells during the culturing in LBL ICC scaffolds. Sox-9 expressed 
81.2±5.2% of cultured cells, which is a sign of activation in all pre-chondrogenic 
mesenchymal condensations. Cells with expression of COL2A is 53.2±3.8%, 
indicating a more active phenotype of chondrogenic status of cells.35 Osteogentic 
markers, RUNX2 and ALP are expressed in 27.3±4.7% and 2.89±1.4% of all 
population respectively. At the early stage of phenotype change, RUNX2 
determines the osteoblast lineage from bone marrow multipotent mesenchymal 
cells, and further induces ALP activity at later stage. Therefore, RUNX2 shows 
dominate expression comparing to ALP on day 7.  However, osteogenic markers 
are still much lower than chondrogenic markers and shows insufficient features for 
osteogenesis towards mature osteocyte or osteoblast. Following a 21 day culture 
period, there was a significant upregulating of preadipocytes gene, ACSL5, in 
BMSCs compared with 2D cultured cells (Figure 5.9), while there is no mature 
adipocyte marker PPARγ2 expressed in BMSCs cultured on ICC scaffold with LBL 
coating. The result shows no sufficient adipogenesis in the 3D culture.  
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Figure 5.9 Quantitative analysis of expression level with markers of Chondrogenic, 
Osteogenic and Adipogenic lineages according to immunofluorescence staining 
images of HS-5 Cells on LBL-modified ICC scaffold coated with 7 bi-layers of 
PDDA/Clay on Day 7 and day 21. (P<0.05) 
 
It was reported largely in vitro and in vivo osteogenic effects of biomimetic 
polymer scaffolds on stem cells50,51. However, the expression of chondrogenic and 
osteogenic markers were found related to the location of cells in the porous 
structure of LBL-modified scaffold. It was noticed that the BMSCs stained with 
chondrogenic markers, COL2A, were mainly present at the center of the cell plaque 
(Figure 5.10a), whereas cells with osteogenic marker, RUNX2, was predominantly 
localized at the periphery of the cell plaque or in contact with the clay surface of 
the pore (Figure 5.10b). HS-5 cells often forms a dense “net” of cells after 
extracted from BMSCs7,43, which appear to be fibroblastoid and secrete significant 
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levels of growth factors in traditional 2D cell cultures. In contact with the LBL-
modified bone-mimetic surface of scaffolds, osteogenesis of HS-5 cells were 
promoted. Meanwhile, the center of the cell net could not sense the cues from the 
environment except the neighbor cells, which promoted chondrogenesis instead.   
Quantitative analysis of the counterstaining images for both RUNX-2 and 
Sox-9 (Figure 5.10c) was processed by ImageJ to examine the overlap of the two 
markers. The result indicated large portion of the RUNX-2 positive cells expressed 
chondrocyte specific markers Sox-9. 21.34±3.2% of HS-5 cells express both 
markers comparing to 81.2±6.0% chondrocyte-like cells among all the population, 
and these cells were located in the plaques rather than adhering to the surface of the 
pore substrate. It was reported RUNX-2 expression in BMSCs can accelerate bone 
formation in healing of critical-sized defects.52 Consequently, the increase of 
expression in center of the HS-5 cell clusters indirectly improve the bone formation 
in 3D environment although the primary cells in the center have lower chance to 






Figure 5.10 Confocal z-stack images of HS-cells aggregates in pores of ICC 
scaffold cultured were taken every 8µm in depth. Cells were stained with COL2A 









The findings reported here indicate that stablished support cells HS-5 line 
extracted from BMSCs is possible to transit their phenotypes during the culturing 
within the 3D ICC scaffold with LBL bone mimetic coating of clay and PDDA. 
This study showed that LBL coating technology applied to 3D tissue engineering 
matrices, with an appropriate surface and mechanical property, can vary the 
morphology of cultured BMSCs aggregation and promote chondrogenic 
differentiation and potentially osteogenic differentiation, at the same time 
suppressing adipogenic differentiation. In addition, this study provides a scientific 
basis for creating in-vitro bone marrow niches for HSCs with supporting stromal 
cells, as well as advancing our understanding towards tissue engineering involving 
BMSCs and surface properties of 3D matrix. LBL surface modification on 3D 
porous ICC hydrogel scaffolds demonstrated this technique can change the surface 
ligands and properties of 3D matrices and thereafter control the cell behavior while 
LBL on 3D structure provides a tool to designing the microenvironment of bone 
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Suggested Future Directions and Conclusion 
 
6.1. Suggested future directions 
6.1.1. Direction for 3D cell culture model 
The size of the cellular spheroids in 3D cell culture used in this dissertation 
work was selected as the diffusion limit of oxygen in tissues is around 150-200μm1. 
Therefore, cells within spheroids in the model here are not expected to suffer from 
hypoxia. However, as a tumor grows to a detectable size, its central region usually 
contains only dead cells. This central region of dead cells is called necrotic core of 
the tumor2,3,4 (Figure 6.1). This properties of the tumor structure regarding to size 
of tumor growth shall also change the distribution and penetration of drugs 
including the nanomedicines due to the different status of cell activities, whereas 
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the preliminary result of Chapter 4 has shown that size-controlled cellular spheroids 
range from 100 to 400μm are an adequate model for studying the process of NP 




Figure 6.1 Metabolic adaptation of tumor growth as penetration of oxygen and 
nutrients decrease in the core of tumor. The necrotic center can be formed when the 
size of tumor spheroid are above 200μm in diameter.2,4 
 
In another aspect, the liver carcinoma cell line used in the primary 
experiments for NP transport study has the limitation to mimic the real human 
primary tissue. In the future work, the study and validation of NP transport 
properties shall be implemented in personalized and human-derived cells and tissue.  
The stem cell culture with sized-controlled EBs successfully incorporated with ICC 
scaffold and LBL technique have shown in chapter 4 and 5, which can be used for 
NP transport in human related and patient-specific tumor tissue, and expected to 
demonstrate unique properties for individual patients and more accurate comparing 




6.1.2. Direction for simulation study 
The random walk model to study the NP transport as two-phase diffusion 
in chapter 3 is simplified based on the assumption of equilibrium condition in 
experimental framework. However, to generalized the model for application of 
other NPs with higher or faster binding/unbinding activity by cells in the spheroids, 
this model shall be consist of the transition state such as cell membrane binding and 
uptake5,6. This is essential for targeted NP transport after extravasation. The 
increase possibility of this transition interrupt the diffusion process and create a 
diffusion barrier at the out layer of the tissue/tumor, which slows down the apparent 
diffusivity Da and results in poor distribution of nanomedicines
7,8. The simulated 
structure of spheroids was simulated by the perfect spheres packed in 3D although 
the cells in the tissue are packed tighter and with uniform intercellular space. 
Therefore, the structure can be represented in the future study by Voronoi 
geometries9 without large pores in 3D domain to improve the accuracy. 
 
6.1.3. Direction for estimation of NP transport in the framework  
This frame work can be applied and generalized for other NPs for the 
diffusion studies. Understanding the effect of charge, size and shape of NPs on 
diffusion processes in tissues represents an essential part of this project.  In the 
future work, CNTs with a different charge using variation of positively, neutral and 
negatively charged organic capping agents/stabilizers should be tested to better 
understand the detailed fundamental mechanism of transport.  Shape of NPs can 
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potentially be a fascinating parameter to vary in respect of permeation studies.  
Comparison of permeation of graphene NPs (Figure 6.2) with small size and aspect 
ratio will be compared to permeation of CNTs. Surface modification of graphene 
and carbon nanoparticles can be accomplished the same way as that for CNTs. 
Moreover, the affinity of NPs with cell membrane influences the transport 
essencially according to the study in this dissertation. Chiral graphene quantum dots 
(GQDs) covalent attached with L/D-cysteine moieties to the edges are the potential 
candidate as the positive control for the framework. The conjugation of L/D-
cysteine to GQDs leads to their helical buckling due to chiral interactions at the 
edges. The preliminary study demonstrated that GQD enantiomer with the left twist 
has stronger tendency to accumulate within the cellular membrane than the opposite 
enantiomer. Thereby, although L/D-GQDs has the same core materials and surface 





Figure 6.2 TEM images of GQDs and the preliminary data of L/D-cysteine 
conjugated GQDs interacted with cell membrane by molecular simulation. 
 
6.1.4. Direction for clinical use of targeted CNTs 
The management of intraocular tumors include systemic treatments such as 
external beam radiotherapy, systemic or intra-arterial chemotherapy, and local 
treatments such as local plaque radiotherapy, removal of eye or in selected cases, 
laser photocoagulation.10,11 Recently, intravitreal chemotherapy injection was used 
in the treatment of selected intraocular tumors such as retinoblastoma or 
vitreoretinal lymphoma.12 However, one of the main reason for failure of main 
retinal tumor response in vitreous is drug penetration. Therefore, drug carriers 
which are capable of deep and fast penetration through all retinal layers as well as 
internal limiting membrane are much needed. 
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Diffusional transport of targeted CNTs was found surprisingly high in the 
chapter 2 and 3. This anomalous trend is attributed to the planar diffusion of CNTs 
along cellular membranes reducing effective dimensionality of diffusional space. 
Preliminary result (Figure 6.3) shows CNT conjugated with epithelial cell-specific 
vitamin, Biotin, (0.1mg/ml) can penetrate through the thick tumor layer of mice 
after injection for 24 h and access the bottom layer of the eyes where it was targeted.  
This property of CNT with selected targeting ligand is promising candidate for local 
injection treatment for intraocular tumors. Intraocular tumors are life-threatening 
cancers that affect every age. They mostly affect choroidal layer, but the others 
intraocular layers including ciliary body, iris and retinal layers.  
 
Figure 6.3 Eye structure (Left) and fluorescent images (Right) show the targeted 
CNT-Biotin (Green) penetrated through tumor cells (Blue) and reached the 





6.2. Concluding remarks 
This dissertation mainly focuses on development and establishment of the 
experimental and conceptual framework for quantitative evaluation of NP transport 
in the tumor mass using 3D cell culture ex vivo and mathematical simulation. The 
most important achievement was developing a distinctive platform, 3D cellular 
spheroid culture in ICC scaffolds and further establishing this platform with 
computer-aided quantification and simulation as a reference system. In addition, 
this work was successfully extended to size-controlled standardized stem cellular 
spheroid culture model and further potentially utilized as an ex-vivo platform for 
human-related and patient-specific nanomedicine characterization and transport 
study. 
Firstly, this work started with utilizing the 3D cell culture and looking for 
the suitable models for NP transport study as the experimental framework. This 
experimental model based on 3D liver carcinoma cellular spheroids culture 
demonstrated promising potential of this research with an increase in complexity 
of structure and functions at closer replication of human tissues, high uniformity 
for standardized data and high transparency for monitoring NP transport in real time 
with high-resolution imaging equipment. The quantification of CNT transport 
extracted from experimental framework contribute tremendously to the finding of 
the fundamental mechanisms of NP transport in tumor tissue. 
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Secondly, improvements have been made in fundamental understanding of 
the mechanisms of transport in tumor tissues. Systematic and quantitative 
investigation have developed the approach to standardize the comparable parameter 
as apparent diffusion coefficients. As such, the fast diffusion of targeted CNT was 
found in chapter 3 contributing to lateral diffusion on cell membrane based on the 
concept of Monte-Carlo simulation of two-phase diffusion in interstitial space and 
cell membrane of tumor tissues. The simulated model with measurable inputs of 
interstitial and membrane diffusion coefficients, equilibrium distribution 
coefficient and patient/disease-specific tumor volume ratios, provided a powerful 
tool for prediction and support as a conceptual framework.  
In addition, improvement of 3D cell culture models have been made 
towards the patient-specific and personalized screening because the transport 
process was highly influenced by cellular membrane interaction with the 
nanomedicine. Stem cell culture have been applied to the experimental models to 
create a platform for personalized drug screening, as well as the size-controlled 
technology by ICC scaffolds fabrication will also provide the promising platform 
to study the transport of NP at the different stage of tumor spheroids with/without 
necrotic cores. Layer-by-layer 3D modification of this cell culture models allows 
more diversity of stem cells culture required supporting cells such as bone marrow 
stromal cells. 
Last but not least, my work on these fundamental behaviors of NPs in 
human tissues/tumors in an aspect of experimental and computational simulation 
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make the first steps toward purposeful engineering of NPs for desired depth of 
tissue penetration.  This research carry a significant impact on different fields of 
knowledge from nanomaterials to biomedical engineering and pharmaceutical 
science. I hope the overall framework of NP transport evaluation in my work can 
significantly contribute to the improvement of the application of nanotechnologies 
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